

Journal Pre-proofs


Electromagnetic fields regulate iron metabolism: From mechanisms to applications

Shenghang Wang, Jiancheng Yang, Chenxiao Zhen, Huiru Wang, Peng Shang

PII: S2090-1232(25)00288-7
DOI: <https://doi.org/10.1016/j.jare.2025.04.044>
Reference: JARE 2158

To appear in: *Journal of Advanced Research*

Received Date: 22 December 2024
Revised Date: 6 April 2025
Accepted Date: 28 April 2025



Please cite this article as: Wang, S., Yang, J., Zhen, C., Wang, H., Shang, P., Electromagnetic fields regulate iron metabolism: From mechanisms to applications, *Journal of Advanced Research* (2025), doi: <https://doi.org/10.1016/j.jare.2025.04.044>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Electromagnetic Fields Regulate Iron Metabolism: from Mechanisms to Applications

Shenghang Wang^{1,2#}, Jiancheng Yang^{3#}, Chenxiao Zhen^{1,2,4}, Huiru Wang^{2,4}, Peng Shang^{2*}

1. Department of Spine Surgery, People's Hospital of Longhua, Shenzhen, China
2. Research & Development Institute of Northwestern Polytechnical University in Shenzhen, Shenzhen, China
3. Department of Osteoporosis, Honghui Hospital, Xi'an Jiaotong University, Xi'an, China
4. School of Life Sciences, Northwestern Polytechnical University, Xi'an, China

#These authors contributed equally to this work.

*Corresponding author:

Peng Shang, Research & Development Institute of Northwestern Polytechnical University in Shenzhen, No. 45, Gaoxin South 9th Road, Nanshan District, Shenzhen, China. E-mail: shangpeng@nwpu.edu.cn

CREDIT Author Statement:

Shenghang Wang: Conceptualization, Data curation, Writing – original draft, Funding acquisition; Jiancheng Yang: Supervision, Writing –review & editing; Chenxiao Zhen: Writing – original draft, Software; Huiru Wang: Data curation, Software; Peng Shang: Conceptualization, Supervision, Writing –review & editing, Funding acquisition.

Electromagnetic Fields Regulate Iron Metabolism: from Mechanisms to Applications

Abstract

Background: Electromagnetic fields (EMFs), as a form of physical therapy, have been widely applied in biomedicine. Iron, the most abundant trace metal in living organisms, plays a critical role in various physiological processes, and imbalances in its metabolism are closely associated with the development and progression of numerous diseases. Numerous studies have demonstrated that EMF exposure induces significant changes in both systemic and cellular iron metabolism.

Aim of Review: This review aims to summarize the evidence and potential biophysical mechanisms underlying the role of EMFs in regulating iron metabolism, thereby enhancing the understanding of their biological mechanisms and expanding their potential applications in biomedical fields

Key Scientific Concepts of Review: In this review, we have synthesized research findings and proposed the hypothesis that the biophysical mechanisms of EMFs regulate iron metabolism involve the special electromagnetic properties of iron-containing proteins and iron-enriched tissues, as well as the modulation of membrane structure and function, ion channels, and the generation and activity of reactive oxygen species (ROS). Then, the review summarizes the latest advances in the effects of EMFs on iron metabolism and their safety, as well as their impact on immunoregulation, cardiovascular diseases, neurological diseases, orthopedic diseases, diabetes, liver injury, and cancer.

Key words: Electromagnetic fields; Iron metabolism; Diseases; Biophysical mechanism

Introduction

Electromagnetic fields (EMFs) are natural environmental factors essential to all living organisms. Earth is a giant magnet, enveloping all life on the planet within a geomagnetic field (GMF) of 20-70 μT , where organisms survive, evolve, reproduce, and die [1]. Meanwhile, advancements in technology have led to increasing exposure to various types of artificial EMFs. These artificial EMFs are now extensively utilized not only in industrial production and communication but also in biomedical applications. For instance, magnetic resonance imaging (MRI), a representative application of EMFs in biomedicine, has revolutionized medical diagnostic technology. In recent years, the biological effects and mechanisms of EMFs, as well as their applications in the treatment of various diseases, have gained growing attention. Various types of EMFs have been increasingly applied in both research and clinical treatment across a range of conditions, including immunoregulation, cardiovascular diseases, neurodegenerative disorders, orthopedic conditions, and cancers [2-6].

Iron is the most abundant transition metal in humans, and the balance of its metabolism is vital and essential for health[7]. On one hand, iron is an essential component of various proteins and a cofactor for many key enzymes, participating in critical physiological processes such as oxygen transport, DNA synthesis and repair,

and the maintenance of mitochondrial function, among others[8]. Systemic iron deficiency has been considered as the direct cause of iron-deficiency anemia and related complications. Additionally, brain iron deficiency has been associated with irreversible cognitive and developmental delays[9]. On the other hand, abnormally increased iron levels in tissues and cells are recognized as triggers for redox imbalance. Iron can also convert relatively inactive O_2 and H_2O_2 molecules into highly active oxygen free radical and hydroxyl radicals by participating in the Fenton reaction, thereby increasing intracellular oxidative stress, and involved in various pathological processes[10]. Iron overload is a pathological condition characterized by the excessive accumulation of iron in tissues and organs, often resulting from genetic disorders, chronic blood transfusions, or metabolic dysregulation[11]. Many studies have demonstrated that iron overload is closely involved in the pathological processes of various orthopedic disorders such as osteoporosis, neurodegenerative diseases like Alzheimer's disease, and cardiovascular diseases like atherosclerosis, etc[11]. Moreover, the excessive accumulation of intracellular reactive oxygen species (ROS) caused by iron could induce a novel form of iron-dependent programmed cell death—ferroptosis[12]. Ferroptosis is one of the key biological mechanisms underlying many iron overload-related diseases [13]. Furthermore, due to the fragile redox balance characteristic of most cancer cells, ferroptosis has emerged as a promising target for cancer therapy.

The regulation of ion transport and metabolism is recognized as one of the biophysical mechanisms of EMFs[14, 15]. Firstly, iron and some iron-containing proteins, owing to their strong natural magnetic moments, are considered key targets of the biological effects of EMFs. Meanwhile, the effects of EMFs on cellular membrane potential and transmembrane ion channels may also be an important pathway to regulate iron metabolism. Moreover, considering the close association between iron and ROS, as well as the substantial research evidence about the modulation of ROS by EMFs, it has been suggested that iron metabolism could be a critical target of EMF-induced biological effects[16, 17]. In addition, EMFs have been shown to regulate cellular and systemic iron metabolism by influencing the enrichment, uptake, and release of iron-containing agents, including iron-based nanoparticles (NPs)[18, 19]. Notably, the effects of EMFs on iron metabolism are not solely determined by the exposure parameters of the field, such as intensity, frequency, and duration, but also influenced by the physiological status of the organism and tissue-specific variations. For example, in our previous study, continuous exposure to 10 T–12 T static magnetic fields (SMFs) for 28 days increased iron levels in the kidneys and liver of mice. 2 T- 8 T SMFs exposure also resulted in an elevation of iron content in the kidneys, but did not significantly change iron levels in the liver of mice[20]. Burchard JF et al also found that 60 Hz, 30 μ T EMFs exposure for 30 days did not change iron levels in the cerebrospinal fluid of ovariectomized cows but reduced iron content in the cerebrospinal fluid of nonlactating pregnant cows [21]. Overall, although the diverse effects of EMFs on iron metabolism make it difficult to systematically summarize, the findings from relevant studies provide valuable insights for the safety assessment of EMFs and their applications in the biomedical field.

This review focuses on the effects of EMFs on iron metabolism and their potential applications in the prevention and treatment of diseases related to iron homeostasis disorders. We first describe the classification and characteristics of EMFs, along with the fundamental concepts of systemic and cellular iron metabolism. Subsequently, we propose several potential biophysical mechanisms through which EMFs regulate iron

metabolism. Furthermore, we discuss the applications and underlying biological mechanisms of EMFs in blood and immunoregulation, and management of iron homeostasis disorders-related diseases such as cardiovascular diseases, neurological conditions, orthopedic diseases, and cancer, among others.

The classification of EMFs

EMFs can be classified into static magnetic fields (SMFs, 0 Hz) and time-varying magnetic fields based on whether the magnetic field intensity and orientation varies with time[22] (Figure 1).

According to the different magnetic field intensity, the SMFs could be further divided into hypomagnetic fields (HyMF, $<5 \mu\text{T}$), weak static magnetic fields (WSMF, $5 \mu\text{T}$ to 1 mT), moderate static magnetic fields (MSMF, 1 mT to 1 T), and high static magnetic fields (HiSMF, $>1 \text{ T}$)[23]. Natural HyMFs are mainly exist in locations distant from the Earth's surface and in extraterrestrial space, such as the magnetic field intensity on the Moon is less than 300 nT [24]. The artificial HyMF environments on Earth are primarily typically achieved using shielding systems made of soft magnetic materials or compensation systems based on Helmholtz coils. The geomagnetic field can be classified as a WSMF, while the magnetic fields generated by common permanent magnets are considered MSMFs. The most common HiSMF environments are primarily produced by superconducting technology, such as the main magnetic field in MRI devices. Currently, artificial HiSMF can exceed 45 T [25].

Based on the difference in frequency, time-varying magnetic fields can be further classified into extremely low-frequency electromagnetic fields (ELF-EMFs, $0\text{--}100 \text{ KHz}$) and radiofrequency electromagnetic fields (RF-EMFs, 100 KHz to 300 GHz), etc[26]. The terahertz fields, infrared, visible light, ultraviolet, and higher-frequency fields such as X-rays and γ rays are considered within the scope of EMFs in physics, but these fields fall outside the scope of this review. Time-varying magnetic fields can be generated by varying currents. For example, alternating current (AC) can produce sinusoidal EMFs, while modulated currents can generate pulsed electromagnetic fields (PEMFs). Additionally, some time-varying magnetic fields, such as rotating magnetic fields (RMFs), can be produced using moving SMF devices. Common sources of ELF-EMFs include power systems and electrical appliances. Notably, ELF-EMFs have significant biomedical applications, such as RMFs for regulating chronic diseases and transcranial magnetic stimulation (TMS) for treating neurological disorders[27–29]. The RF-EMFs are not only widely used in mobile communication technologies, including current 5G communication devices, but also extensively applied in diathermy therapy[30, 31].

Iron metabolism

Iron metabolism is precisely regulated in the body to maintain a relatively balanced state. Approximately 2% of human genes encode iron-containing proteins, and over 6% of all enzymes are dependent on iron [32]. Both iron deficiency and iron overload at the tissue, organ, or cellular levels are associated with impairments in normal physiological functions [7, 33]. Iron metabolism in organisms can be broadly categorized into systemic iron metabolism and cellular iron metabolism, which are interconnected and regulated through multiple signaling pathways. These include the

hepcidin-ferroportin (FPN/SLC40A1) axis, the iron-regulatory protein (IRP)–iron-responsive element (IRE) network, and the nuclear factor erythroid 2-related factor 2 (NRF2) regulatory hub, among others. Additionally, as an iron-dependent form of programmed cell death, ferroptosis has recently emerged as a key focus in the study of iron metabolism[34] (Figure 2).

Systemic iron metabolism

Systemic iron metabolism refers to the regulatory processes involved in the absorption, transport, storage, and reutilization of iron throughout the body. In humans, systemic iron is primarily absorbed by the epithelial cells of the duodenum from the diet, at a rate of approximately 1–2 mg per day [8]. Within duodenal epithelial cells, iron is processed, transported, and released into the bloodstream through the basolateral membrane. Then, iron bound to transferrin (Tf) in blood, and is transported to tissues for storage or utilization. Iron in the body can be broadly categorized into functional iron and storage iron. Functional iron mainly exists in the heme structures such as hemoglobin (Hb) and myoglobin (Mb), with Hb iron in red blood cells accounting for approximately 70% of the total body iron. The damaged or senescent red blood cells could be phagocytosed by macrophages, and Hb iron is released and reused, which supplied more than 90% of the iron for utilization in organism[35].

Excess iron in the organism is primarily stored in hepatocytes in the liver and in the reticuloendothelial systems of the spleen and bone marrow. Notably, the human body lacks a specific iron excretion pathway, and iron loss is primarily via shedding of cells and bleeding to maintain a relatively stable total organism iron level. Systemic iron metabolism is mainly regulated by the hepcidin-FPN axis[36]. Hepcidin, encoded by the HAMP gene, is a key regulator in the systemic iron metabolism and is primarily secreted by the liver. FPN, a membrane iron transporter, is currently the only known channel for iron export in mammals. Duodenal epithelial cells, stem cells, and macrophages all express high levels of FPN, participating in the regulation of systemic iron metabolism. Hepcidin binds to the extracellular domain of FPN on the cell membrane, triggering its internalization and subsequent degradation in lysosomes, thereby reducing cellular iron efflux. Abnormal expression and function of hepcidin is often accompanied by severe systemic iron metabolism disorders. For instance, hepcidin deficiency can lead to iron overload disorders such as hereditary hemochromatosis, while elevated hepcidin levels are associated with conditions like iron-refractory iron deficiency anemia (IRIDA) and anemia of inflammation[37].

Cellular iron metabolism

Cellular iron metabolism can be divided into iron uptake, utilization, storage, and efflux[8]. The majority of cellular iron uptake is mediated by the transferrin receptor (TfR), which binds to iron-loaded transferrin (Tf) and facilitates the internalization of the Tf–TfR complex. Within the acidic environment of endosomes, Fe^{3+} is released from Tf–TfR complex, subsequently reduced to Fe^{2+} by six-transmembrane epithelial antigen of the prostate 3 (STEAP3), and then transported into the cytoplasm via divalent metal transporter 1 (DMT1/SLC11A2). DMT1 is also the primarily mediator of the uptake of non-transferrin bound iron (NTBI). Additionally, the zinc transporters Zrt- and Irt-like protein 8 (ZIP8) and ZIP14 can also mediate NTBI uptake. Moreover, heme

can be directly absorbed by cells via prolipoprotein receptor-related protein 1 (LRP1; also known as CD91), heme-responsive gene 1 protein (HRG1/SLC48A1), and feline leukemia virus subgroup C receptor 2 (FLVCR2/SLC49A2). Furthermore, some cells can directly uptake ferritin via Scara5[38]. Once inside the cell, iron can be directly utilized in critical physiological processes such as enzymatic activity and cellular respiration. In this process, a large fraction of iron enters mitochondria through mitoferrins (MFRNs) to participate in the assembly of Fe-S cluster and the synthesis of heme. Unutilized intracellular iron exists in the labile iron pool (LIP), which can be directly used by the cell and is also an important source of intracellular ROS[38].

Excess intracellular iron is stored in ferritin, a protein capable of housing up to 4,500 iron atoms. Ferritin consists of 24 subunits, primarily categorized into heavy (FTH) and light (FTL) chains. Nuclear receptor coactivator 4 (NCOA4) could mediate the autophagic degradation of ferritin within lysosomes, and released iron back into the LIP, which process termed ferritinophagy[39]. During cellular iron efflux, Fe^{2+} is primarily transported to the extracellular space by FPN, and oxidized to Fe^{3+} by ceruloplasmin (Cp) or heparan sulfate, allowing it to rebind to Tf. Additionally, ferritin could be secreted to extracellular environment by lysosome during ferritinophagy in hepatocytes, macrophages, and renal tubular cells. Furthermore, despite ongoing debate, FLVCR1 on the cell membrane is believed to directly export heme from the cell, a process important for preventing excessive heme accumulation and enabling its transfer from macrophages to developing erythroblasts.

Regulatory Pathways of Iron Metabolism

The balance of systemic and cellular iron metabolism is maintained through a complex regulatory system. In addition to the previously mentioned hepcidin-FPN axis, the IRP/IRE network and the NRF2 regulatory hub also play crucial roles in this process[37]. IRPs include two homologous factors: IRP1 (also known as cytoplasmic aconitase) and IRP2. IRP1 and IRP2 can bind to IREs located in the untranslated regions (UTRs) of target mRNAs encoding iron metabolism-related proteins, thereby regulating both the translation of ferritin and FPN mRNA and the stability of TfR and DMT1 mRNA. Under iron-deficient conditions, the interaction between IRPs and the IREs of target mRNAs prevents the small ribosomal subunit from binding to the mRNA, thereby inhibiting the translation of ferritin and FPN. Conversely, when intracellular iron levels are sufficient, iron binds to IRPs, causing their dissociation from IREs, thereby promoting the translation of ferritin and FPN while reducing the stability of TfR and DMT1 mRNA [40]. NRF2 was initially identified for its role in erythropoiesis and was later recognized as a central regulator of iron metabolism. NRF2 regulates the intracellular labile iron pool (LIP) by upregulating ferritin and ferroportin (FPN)

expression, while its inhibition promotes NCOA4-mediated ferritinophagy[41, 42]. Additionally, NRF2 can regulate hepatic hepcidin synthesis by modulating bone morphogenetic protein 6 (BMP6), thereby indirectly regulating systemic iron metabolism. NRF2 also modulates macrophage heme uptake via HRG1 expression and regulates heme degradation through heme oxygenase 1 (HMOX1). Furthermore, as a key regulator of cellular redox homeostasis, NRF2 plays a protective role against ferroptosis by upregulating genes such as quinone oxidoreductase 1 (NQO1) and heme oxygenase-1 (HO-1)[43].

Ferroptosis

Ferroptosis is a non-apoptotic form of programmed cell death, with one of the key triggering factors is the accumulation of excess redox iron due to dysregulated iron metabolism [44]. Compared to other types of programmed cell death, increased intracellular membrane lipid peroxides due to the reaction of iron or iron-containing enzymes with oxygen and polyunsaturated fatty acid (PUFA) is the defining characteristic of ferroptosis[45]. The regulation of LIP levels has been shown to influence cellular sensitivity to ferroptosis, and iron chelators such as deferoxamine (DFO) and deferiprone (DFP) can protect cells from ferroptosis[46]. Therefore, although the exact role of iron in ferroptosis remains unclear, ferroptosis is still considered an essential component of iron metabolism research.

The potential biophysical mechanisms and characteristics of EMFs in regulating iron metabolism

As a form of physical stimulation, the effects of EMFs on iron metabolism are not limited to the regulation of iron metabolism-related molecular expression but also involve multiple biophysical mechanisms. First, EMFs directly interact with various iron-containing biomacromolecules, including numerous iron-binding proteins, while differences in iron content among tissues may also influence tissue responses to EMF exposure. Additionally, EMFs modulate membrane structures and the states of ion channels, thereby regulating iron transmembrane transport. Furthermore, due to the intricate relationship between intracellular iron and reactive oxygen species (ROS), EMFs can regulate iron metabolism by modulating oxidative stress levels, particularly influencing the spin states of radical pairs. Due to the complex interactions among these biophysical mechanisms, the regulation of iron metabolism by EMFs varies depending on parameters such as intensity, gradient, frequency, and exposure duration, while also exhibiting characteristics of dose dependence, window effects, and specificity for different tissues and cell types (Figure 3).

The direct effects on iron enriched protein and tissues

Iron in proteins can alter their magnetism, thereby affecting their movement and physiological functions in the presence of EMFs. For instance, Hb, as the most well-known iron-containing protein, provides the necessary oxygen for the body to maintain normal energy metabolism. The magnetism of Hb is related to its state, oxyhemoglobin (oxyHb) and carbonmonoxyhemoglobin are diamagnetic, while deoxyhemoglobin (deoxyHb) is magnetic[47]. When moving in an inhomogeneous magnetic field, red

blood cells containing paramagnetic hemoglobin exhibit noticeable displacement toward the stronger magnetic field. This displacement is proportional to the square of the paramagnetic moment of hemoglobin in the cells[48]. Furthermore, studies have found that sufficiently high EMFs can affect Hb diffusion. When the magnetic field strength exceeding 22.8T, the diffusion of deoxyHb is impacted, while fields stronger than 25.7T influence the diffusion of oxyHb[49]. Accordingly, EMFs could mediate the transport of oxygen and the fate of red blood cells through interactions with Hb, thereby regulating systemic iron metabolism. Meanwhile, the function of iron-containing protein can also be regulated by EMFs. As iron storage protein, ferritin consists of a cage-like structure composed of 24 subunits. The iron is mainly stored in the cage as form of a ferrihydrite-like mineral core, which gives ferritin its superparamagnetic properties[50]. Oscar et al. found that 1 MHz, 30 μ T RF-EMFs exposure significantly decreased the iron intake rate of ferritin. This effect is non-thermal and depends on the frequency-amplitude product of the magnetic field [51, 52]. Hernández-Morales M et al. also found that exposure to 180MHz, 12 μ T RF-EMF increased LIP and upregulated intracellular ROS level in a ferritin-dependent manner, suggesting that EMF exposure promotes iron release from ferritin [53]. In these studies, it was observed that due to magnetization lag, ferritin's internal energy increases when exposed to time-varying magnetic fields. This increased energy will diffuse to the surroundings, altering the molecular dynamics and functioning of the protein cage's subunits, and changing iron intake and release of ferritin. Besides, SMFs have been shown to alter the release of iron from ferritin. Chen et al. found that 1.4 mT - 5.0 mT SMF exposure increased intracellular ROS levels by promoting the release of iron from ferritin, which could be attenuated by the addition of ROS inhibitors or iron chelator[54]. However, it remains uncertain whether this process is due to changes in the molecular dynamics and function of ferritin itself, as our previous study found that exposure to a 0.2–0.4 T SMF increased the LIP level by promoting ferritinophagy[55]. Furthermore, iron-sulfur cluster assembly 1 (IscA1), also known as magnetoreceptor (MagR), is an important magnetic sensitive protein in organisms, which have been indicated contains a very high iron content and serves as a scaffold protein and iron donor, participating in the assembly of iron-sulfur clusters[56]. Moreover, the overexpressing of pigeon MagR has been shown to increase the expression of iron uptake related genes in *E. coli* cells[57]. Therefore, the role of magR in the regulation of EMFs on iron metabolism also deserves further investigation.

The iron content of tissues may influence their electromagnetic properties, thereby affecting their response to EMFs. The biological effects of EMFs may primarily be attributed to differences in magnetic susceptibility (χ) under SMFs. Dubiel et al. found that the distinct uniaxial magnetic anisotropy characteristics of brain and liver are related to variations of iron content and its existing forms tissue[58]. Studies have found that the major organs of iron-overloaded mice exhibit higher magnetic susceptibility[59]. Additionally, the increased tissue iron content has been proved to be a major contributing factor to the elevated magnetic susceptibility of the spleen and liver in NRF2^{-/-} mice[60]. In time-varying magnetic fields, dielectric properties appear to play a more prominent role [61]. Compared to normal tissues, tumor tissues typically exhibit higher dielectric permittivity and conductivity values [62–64]. It can be attributed not only to the higher water content in tumor tissues but also to the higher iron content.

However, magnetism is an intrinsic property of matter, and virtually all molecules

can be influenced by EMFs, although their sensitivity and responses vary depending on their magnetic properties. Notably, some non-iron-containing molecules, such as ROS and certain metal enzymes, also exhibit relatively high magnetic susceptibility, making them sensitive to EMF exposure. Given the current limited understanding of the magnetic properties and EMF responsiveness of molecules involved in iron metabolism, it is possible that EMFs may regulate iron metabolism indirectly through interactions with non-iron-containing biomacromolecules or structural components of tissues.

Membrane permeability, potential and ion channels

Cellular iron uptake, utilization, and efflux involve the transmembrane transport of iron ions and iron-binding proteins. Meanwhile, membrane structure and membrane potential, and the state of ion channels on the membrane can all affect the transport of iron, thereby influencing iron metabolism. The biological effects of EMFs are related to their regulation of membrane potential and ion channels[65, 66]. Firstly, EMFs can mediate the ion diffusion and transport via the Lorentz force and alter the membrane potential[67, 68]. On one hand, EMF exposure can reorganize the permanent phospholipid dipoles in the membrane structure, influencing its shape and potential [69]. On the other hand, the membrane structure has a higher electrical resistance, while transmembrane proteins have higher charge permeability making the conformation of these proteins more susceptible to changes induced by EMF exposure [70]. Voltage-gated ion channels (VGCs) are crucial pathways for ion transport in cells, containing domains rich in charged residues, known as voltage-sensing domains (VSDs), which undergo conformational changes in response to voltage fluctuations across the membrane [71]. Many studies have indicated that both acute and chronic EMFs exposure can enhance ion transport mediated by various VGCs, which may be attributed to the effects of EMFs on the VSD and pore-forming domain of VGCs[66, 72-74]. Although no specific iron-VGCs have been identified, iron can non-specifically enter cells through various types of VGCs [75-77]. Additionally, EMFs can regulate cellular iron uptake by regulating mechanosensitive ion channels on the cell membrane[78]. Piezo1 primarily recognized as a mechanosensitive calcium ion channel, has also been implicated in iron uptake [79]. Studies have shown that EMFs can influence the expression and activation state of Piezo1[80, 81]. These conformational changes of Piezo1 may not be directly caused by EMF induced mechanical stimulation, as such stimulation requires forces exceeding the pN, which is far greater than the magnitude of forces generated by the EMFs in these studies.[82]. However, it is still possible for EMFs to directly affect the opening of mechanosensitive ion channels either through direct interaction or indirectly through cell membrane deformation, as long as the intensity gradient or energy of EMFs is sufficient. For example, external EMFs have been reported to induce ion oscillations, leading to membrane oscillations and subsequent alterations in the activity of mechanosensitive channels [83].

The interaction between ROS and iron metabolism

EMFs can modulate intracellular ROS levels through multiple pathways [84-87]. Radicals, important components of ROS, are characterized by unpaired electrons in their outer shells. The effect of EMFs on radical pairs is hypothesized to be a key physical mechanism underlying the biological effects of EMFs and one of the fundamental bases for biological sensitivity to magnetic fields[88, 89]. Studies have shown that the singlet-triplet transitions and recombination of radical pairs can be

regulated by magnetic fields, thereby influencing intracellular ROS levels [90, 91].. Additionally, EMFs have been reported to alter intracellular ROS levels by modulating the activity of antioxidant enzymes [16]. The intracellular ROS levels are closely associated with iron metabolism. On one hand, intracellular iron can increase ROS levels by participating in the Fenton reaction, and iron deposition within ferritin is accompanied by the generation of a small amount of hydroxyl radicals. On the other hand, ROS can actively regulate the process of iron metabolism[92-94]Hydrogen peroxide can promote the binding of IRP1 to IREs and induce the iron atom release from cytosolic aconitase by directly reacting with [4Fe-4S] cluster, thereby influencing iron metabolism[95, 96]. Superoxide and hydroxyl radicals can also facilitate the release of iron from transferrin and enhance cellular iron uptake[97, 98]. Additionally, studies have shown that ROS (including radical pairs) can regulate the expression and function of iron metabolism-related genes and proteins. [98, 99]. Moreover, ROS can indirectly modulate iron metabolism by reducing the activation of the IRP/IRE network and promoting NRF2 expression [100]. Many studies focus on the regulation of iron metabolism by EMFs has also reported concurrent changes in ROS levels[101-104]. The increase in intracellular ROS levels induced by EMFs is typically accompanied by upregulated expression of iron uptake-related genes and an elevated LIP. In contrast, the decrease in intracellular ROS levels under EMF exposure is associated with the upregulation of iron storage and export-related genes, along with a reduction in LIP levels. Although the upstream-downstream regulatory relationship between intracellular iron metabolism and ROS levels under EMFs exposure remains unclear, we speculate that EMF-mediated ROS regulation is an important biophysical mechanism underlying its modulation of iron metabolism.

The characteristics of EMFs in regulating iron metabolism

Due to the complex interactions among these biophysical mechanisms, the regulation of iron metabolism by EMFs varies depending on parameters such as intensity, gradient, frequency, and exposure duration, while also exhibiting characteristics of window effects and specificity for different tissues and cell types.

One of the most prominent features of EMF-mediated regulation of iron metabolism is its dependence on EMF parameters. For intensity, HyMF have been shown to increase serum and femur iron content in mice, whereas 1-2T HiSMF can decrease iron levels in these organs[105, 106]. For gradient, MSMFs with lower gradients have been shown to reduce iron overload in diabetic mice, whereas high-gradient SMFs fail to produce the same effect[102, 107]. For frequency, ELF-EMF at 7.5 Hz have been shown to reduce intracellular iron levels, and its inhibitory effects on tumor cells were mitigated by ferric ammonium citrate (FAC), while the antitumor effects of 134 kHz RF-EMFs were attenuated by iron chelators[108, 109]. The differential responsiveness of iron-containing proteins to EMFs is a key factor underlying the parameter-specific regulation of iron metabolism by EMFs. For instance, hemoglobin remains largely unaffected under low EMF strength or gradient, while its movement becomes subject to magnetic control in high-gradient EMFs, which has even been exploited for applications such as red blood cell separation[49, 110]. The differential responsiveness of membranes and membrane-bound ion channels to EMFs is another critical reason for the parameter-specific regulation of iron metabolism by EMFs [111]. On one hand, different types of ion channels require distinct membrane potential thresholds or force for activation. On the other hand, EMFs with varying parameters exert different levels

of electrical stimulation, tension on membrane structures, thereby leading to diverse biological effects. Additionally, the sensitivity of ion channels to EMF exposure is also related to their type and the frequency of the EMF. Furthermore, the effects of EMFs on ROS have shown varying results depending on the exposure parameters and cell types [16, 106, 112-119]. Therefore, the differential regulation of ROS by various EMF parameters is also one of the key reasons underlying the parameter-specific effects of EMFs on iron metabolism.

The specificity of EMF-regulated iron metabolism in different tissues and cell types is also a significant manifestation of the complex interplay among the various biophysical mechanisms through which EMFs exert their effects on iron homeostasis. First, the iron content and the distribution of iron-containing proteins vary across different tissues. The liver and spleen, which are rich in iron, and often exhibit more pronounced changes in iron metabolism-related indicators under EMF exposure[17]. It was reported that the enriched iron content in many types cancer cells results in a higher magnetic susceptibility ($\chi_{\text{cancerous}} > \chi_{\text{healthy}}$), making them more sensitive to SMFs[120]. In addition, the distribution of membrane ion channels and the levels of intracellular ROS also vary across different tissues and cell types. For example, neuronal cells typically possess a higher density of membrane-bound ion channels, the metabolically active cells—such as tumor cells tend to exhibit elevated intracellular ROS levels[121, 122]. Moreover, the organism's inherent homeostatic mechanisms allow it to gradually adapt to external stimuli, thereby reducing sensitivity to EMFs. This adaptive capacity may be one of the key reasons underlying the "window effect" observed in the regulation of iron metabolism by EMFs. In addition, studies have shown that intracellular levels of ions such as potassium and calcium exhibit periodic fluctuations, and EMFs with specific frequencies can induce resonance-like responses with these ions, thereby eliciting biological effects [123]. Although it remains unclear whether intracellular iron levels exhibit periodic changes, they have been shown to undergo dynamic fluctuations[124]. Furthermore, the resonance frequencies of different iron metabolism-related molecules and ion channels lead to their differential responses to EMFs of varying frequencies [125-127]. Therefore, resonance-like interactions between intracellular iron ions or iron metabolism-related molecules and electromagnetic fields may also represent a potential reason for the window effects of EMFs on the regulation of iron metabolism, influenced by factors such as intensity, frequency, and exposure duration.

The effects of EMFs on iron metabolism and its relationship to diseases

The safety of EMFs and their potential therapeutic applications in various diseases have garnered increasing attention, with research into their biological mechanisms advancing steadily. Recently, changes in iron metabolism have become a focal point in studies on the biological effects of EMFs[17]. Many studies on the biosafety of EMFs have reported changes in iron metabolism. Meanwhile, iron metabolism is involved in the regulation of EMFs on immunoregulation, and the progression of neurological diseases, cardiovascular diseases, orthopedic diseases, diabetes, liver injury, and cancer[102, 118, 128-138] (Figure 4). Additionally, studies have demonstrated that iron metabolism is involved in the regulation of EMFs on ROS and ferroptosis[55, 112, 119, 139]. Moreover, in combination with iron metabolism-regulating drugs or iron oxide nanoparticles, EMFs have been observed to exhibit synergistic or antagonistic effects on iron metabolism regulation[108, 140-143].

The relationship between EMFs biosafety and its regulation on iron metabolism

Current research on the relationship between electromagnetic field (EMF) biosafety and its regulation of iron metabolism primarily focuses on iron metabolism-related indicators in the nervous system and blood. Red blood cells, hemoglobin (Hb), transferrin, and other iron-related parameters in the blood are all important indicators of systemic iron metabolism. Thalassemia, a hereditary hemolytic anemia, necessitates regular blood transfusions to maintain adequate Hb levels. However, due to the lack of efficient iron elimination mechanisms in the human body, thalassemia patients are often experience iron overload and require additional iron chelation therapy[144]. Various studies have reported that 1 hour per day 128 mT SMF exposure increased the transferrin content in serum and iron content in spinal cord, while decreased Hb and iron concentration in plasma[128, 145-148]. It is suggested the potential of EMF-based therapies to exacerbate iron overload in patients receiving blood transfusions. Conversely, the risk of EMF-induced anemia has also been extensively studied. 50 Hz, 1.35 mT ELF-EMF exposure for 2 hours per day over a period of 2 months did not significantly affect the serum Fe^{3+} concentration in SD rats[129]. Similarly, Devevey L et al. found that long-term exposure (3 to 16 weeks) to a 50 Hz, 500 μT ELF-EMF decreased the total percentage of cells in the red cell lineage in blood without inducing anemia-related symptoms [130]. Furthermore, a study reported that exposure to EMFs near 50 Hz high-voltage transmission lines, although it did not cause anemia, led to a decrease in serum iron levels in more than 48% (15/31) of males and more than 38% (13/34) of females[149]. In addition, the effects of RF-EMFs generated by mobile devices on iron status in blood have also been explored. Çetkin M et al. reported that the RF-EMF generated by GSM mobile phone systems reduced the serum transferrin unsaturated iron-binding capacity and total iron-binding capacity in rats[150]. El-Maleky NF et al. found that 60 minutes per daily mobile phone EMFs exposure for 6 months increased the serum ferritin and iron concentration in rats, while simultaneously reducing serum iron, plasma Hb, hematocrit (HCT), mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH) levels[30]. Overall, these studies indicate that EMFs can influence iron metabolism markers and components in the blood. These findings suggest the therapeutic potential of EMFs in treating iron metabolism disorders in blood, while emphasizing the importance of addressing these effects in EMF safety and risk management.

Due to the changes in electrical potentials accompanying neural signal conduction, the nervous system is very responsive to EMFs stimulation. Changes in iron metabolism within the nervous system have been observed in many studies assessing the biological safety of EMFs. Kopani M found that exposure to 1788 MHz RF-EMF generated by GSM mobile phone systems increased iron deposition in the cerebellum of rabbits [31]. Meanwhile, studies have indicated that EMFs could regulate the function and status of brain by altering the blood-brain barrier permeability to iron [151, 152]. Furthermore, 60 Hz, 10 μT ELF-EMF exposure for 24 hours has been shown to increase the occurrence of DNA single-strand and double-strand breaks in rat brain cells, and these effects could be inhibited by the iron chelator deferiprone[153]. In addition, the effects of the EMFs on behavior may be related to its regulation of iron metabolism in the nervous system. Abdelmelek et al. conducted a study using the plus-maze test and found that treatment with FeSO_4 alone did not affect the activity patterns of mice. However, when combined with 128 mT SMF exposure, it significantly reduced the

number of entries and time spent in the open arms, indicating higher anxiety levels in the mice[154]. Interestingly, their related studies found that both the SMF and FeSO₄ treatment alone impaired the spatial learning abilities of mice in morris water maze test, while combined treatment significantly improved the spatial memory abilities of mice compared to the SMF treatment alone [155]. Several studies have also reported that electromagnetic fields exert no significant influence on iron metabolism within the nervous system. For example, Aldinucci et al. found that 50 Hz, 2 mT ELF-EMF exposure had no significant changed free iron release in synaptosomes[135, 156]. Maaroufi et al. also found that 900 MHz RF-EMF exposure interfered spontaneous exploratory behavior in rats, and the intraperitoneal injection of ferrous sulfate induced iron overload has not exacerbated these effects[157]. Nevertheless, the effects of EMFs on iron metabolism should still be considered an important factor when assessing their safety for the nervous system.

In addition, some epidemiological research reported that EMFs may be a risk factor for cancer and male infertility[158, 159]. Dysregulated iron metabolism is a hallmark of cancer cells and also a significant contributor to male infertility[160-162]. However, the relationship between EMFs exposure, its potential role in cancer development and reproductive health, and its regulatory effects on iron metabolism remains to be further investigated.

Overall, the safety risks associated with EMFs are closely linked to their impact on iron metabolism, with oxidative stress resulting from iron dysregulation being one of the primary sources of damage. Therefore, to mitigate the biosafety risks posed by EMFs, potential protective strategies may include not only limiting EMF exposure and administering iron-regulating agents, but also supplementing with antioxidants to reduce oxidative stress.

The effects of EMFs on iron metabolism in immunoregulation

The immune system plays a crucial regulatory role in various physiological processes, including infection, wound healing, aging, and cancer. Iron not only participates in innate immune responses by regulating macrophage polarization, neutrophil recruitment, and natural killer (NK) cell activity but it also involved in adaptive immunity through modulating lymphocytes activation[163]. Extensive studies indicated that EMFs mediated immunoregulation by regulating iron metabolism and redox status. Some studies suggested that EMFs exposure was closed to immune system disturbance and may pose health risks[164, 165]. Nevertheless, the immunomodulatory potential of EMFs has also been extensively explored in research aimed at treating various disease[166, 167].

Innate immunity

Macrophages, a type of innate immune cells, play a crucial role in inflammation, wound healing, and tumor immunity. It can be broadly classified into two subtypes: classically activated (M1) phenotype and alternatively activated (M2) phenotype. M1 macrophages mainly exert pro-inflammatory functions, whereas M2 macrophages mainly exert anti-inflammatory functions. Iron availability influences macrophage polarization, with iron abundance promoting M1 polarization and iron deficiency favoring M2 polarization [163, 168]. Macrophages are key cells in the systemic regulation of iron metabolism, supplying the majority of plasma iron.

RAW264.7 cells, a mouse mononuclear macrophage cell line, are widely used in in vitro studies of macrophage polarization and can differentiate into osteoclasts when induced by receptor activator of nuclear factor-kappa B ligand (RANKL). Our previous study found that 16 T SMF decreased the iron content and the expression of TfR1, DMT1, and FTH1 in RANKL-induced RAW264.7 cells, while increasing FPN expression[131]. It suggests the potential for EMFs to regulate the fate of macrophages by regulating iron metabolism. Notably, the effects of EMFs on macrophage polarization vary depending on parameters such as intensity and frequency[169]. However, the effects of EMFs with different parameters on macrophage iron metabolism and polarization are still unclear. In addition, EMFs have been shown to modulate the functions of NK cells and neutrophils by regulating ROS levels. Various studies showed that ELF-EMFs exposure decreased the activity of natural killer (NK) cells, whereas SMF enhances their cytotoxic capacity [170-172]. Intracellular ROS levels, which are closely related to iron metabolism, play a pivotal role in the function of NK cells and neutrophils [173, 174]. Excessive accumulation of ROS under inflammatory or oxidative conditions could impair the physiological function of monocytes. Patruno et al. reported that 50 Hz, 1 mT ELF-EMF exposure for 1 h decreased intracellular ROS levels in human monocyte THP-1 cells by promoting NRF2 nuclear translocation and activating the NRF2/HO-1 signaling pathway[112]. As mentioned above, NRF2 is widely regarded as a key regulator of iron metabolism. Moreover, the NRF2/HO-1 pathway is also considered a crucial regulatory signaling pathway in ferroptosis. Therefore, the above evidence suggest that EMFs could influence the fate of macrophages, NK cells, neutrophils and monocytes via regulating iron metabolism.

Adaptive immunity

Adaptive immunity, primarily mediated by lymphocytes, is a crucial immune mechanism for combating infectious and malignant diseases [175]. Lymphocytes are highly sensitive to EMFs and are commonly used to assess the biological safety of EMFs. Studies have shown that EMFs can exacerbate lymphocyte damage caused by iron overload. 7 mT SMF and 1.5W/kg, 930 MHz RF-EMF acute (5 and 15 min) exposure did not significantly affect physiological state of lymphocytes, but intensified the increase in intracellular ROS levels and apoptosis induced by FeCl₂[132, 176]. Furthermore, 7 mT SMF and 50 Hz ELF-EMF have been indicated caused DNA damage in lymphocytes when combined with FeCl₂ [113]. These findings demonstrate that EMFs can synergistically enhance intracellular ROS generation when used with iron preparations, leading to cell damage. However, several studies have also found that certain EMFs reduced intracellular oxidative stress levels, and increased activity of lymphocytes. Zmyslony M et al. found that 50 Hz, 40 mT ELF-EMF parallel to the GMF direction exposure decreased intracellular ROS in lymphocytes [177]. Additionally, several studies have indicated that combination treatment of EMFs and iron-based NPs enhanced the activation and anti-tumor effects of T cells[178]. All the above results suggested that the effects of EMFs on lymphocyte iron metabolism and ROS represented a significant risk factor for adaptive immunity. However, optimizing EMF parameters and regulating iron levels in the lymphocyte environment could help mitigate these risks and potentially enhance adaptive immunity.

The effects of EMFs on iron metabolism in cardiovascular diseases

Abnormal iron metabolism has been identified as a trigger for various cardiovascular diseases (CVDs), including hypertension, thrombosis, atherosclerosis, and myocardial ischemia–reperfusion injury [133]. While EMFs have been considered a potential risk factor for cardiovascular diseases, they are also widely applied in the prevention and treatment of these conditions [5].

Hypertension, thrombosis, and atherosclerosis

Epidemiological studies have shown that serum iron levels are negatively correlated with the prevalence of hypertension, while transferrin levels are positively correlated with hypertension prevalence. Both excessively low and high serum ferritin levels have been associated with an increased risk of hypertension[179]. Systemic iron deficiency is widely recognized as one of the causative factors of thrombosis, while chronic use of iron supplements, such as dextran iron, has also been shown to increase thrombosis risk by inducing vascular oxidative stress[180, 181]. The regulatory effects of EMFs exposure on blood flow and blood pressure had been widely confirmed by both animal and clinical studies[182, 183]. Meanwhile, studies have shown a mitigating effect on iron-induced hypertension and related thrombosis in animal models. Li Q et al. found that 400 mT and 600 mT SMFs exposure for 60 days decreased the blood pressure in FeCl₃ treated rats. Moreover, 200 mT SMF increased the thrombolytic agent tissue-type plasminogen activator (tPA) content, and 600 mT SMF decreased thrombus protein content in FeCl₃-induced arterial thrombosis rats [184]. These findings indicate that EMFs have the potential for therapeutic effects in the processes of hypertension and thrombosis caused by iron metabolism disorders.

Atherosclerosis is a prevalent cardiovascular disease worldwide, characterized by high morbidity and mortality rates[185]. Although the relationship between abnormal iron metabolism and atherosclerosis remains controversial, many atherosclerotic patients exhibit symptoms of iron overload. Moreover, both animal and clinical studies have indicated that alleviating iron overload were contributed to mitigating the symptoms of atherosclerosis [186, 187]. Many studies indicated that EMFs inhibit the progression of atherosclerosis by biologically reducing the oxidation rate of low-density lipoprotein (LDL), as well as physiologically decreasing blood viscosity and enhancing blood shear stress [188, 189]. Although direct evidence linking EMFs to the alleviation of atherosclerosis through their regulation of iron metabolism is still lacking, studies have demonstrated the involvement of EMFs in the inhibition of atherosclerosis through their influence on calcium ion metabolism[190]. During the progression of atherosclerosis, the proliferation, migration, and adhesion of vascular smooth muscle cells (VSMCs) was excessively activated. Li et al. found that 5 mT SMF exposure suppressed the proliferation, migration, and adhesion of human umbilical artery smooth muscle cells (hUASMCs) by inhibiting integrin β 1 clustering and reducing cytosolic free calcium concentration [191]. The regulation of ion channel opening states on the cell membrane by EMFs is a key mechanism for modulating intracellular calcium levels, and most calcium ion channels can nonspecifically mediate the transmembrane transport of iron ions[77, 192]. Therefore, the regulation of iron metabolism by SMF may also be involved in inhibiting the proliferation, migration, and adhesion of VSMCs.

651 Ischemia-reperfusion injury

652 Ischemia-reperfusion injury is a common clinical complication observed in
 653 various organs, including the heart, liver, kidneys, and brain. Ferroptosis is one of the
 654 main driving factors underlying ischemia-reperfusion injury[193]. Ferroptotic oxidized
 655 phosphatidylethanolamine species was accumulated in the mitochondria of heart during
 656 ischemia-reperfusion injury, while iron chelators and ferroptosis inhibitors effectively
 657 alleviated acute and chronic myocardial ischemia-reperfusion injury[133]. Ma F et al
 658 found that 30 Hz PEMF (X-axis 0.22 ± 0.05 mT, Y-axis 0.20 ± 0.05 mT, Z-axis
 659 0.06 ± 0.02 mT) exposure reduced the apoptosis of myocardial cells and improved
 660 myocardial ischaemia-reperfusion injury in rats. Meanwhile, PEMF exposure
 661 significantly decreased ROS levels in primary neonatal rat cardiac ventricular myocytes
 662 (NRCMs) induced by hypoxia/reoxygenation (H/R) in vitro[114]. Similarly, 20 Hz, 4.5
 663 mT PEMF exposure suppressed ROS generation and enhanced cell viability in neonatal
 664 rat cardiomyocytes treated with hypoxia/reoxygenation in vitro [194]. The Fe^{2+}
 665 involved Fenton reaction is the major source of ROS during ferroptosis. Therefore, the
 666 protective effect of the EMFs on ischemia-reperfusion injury may also be related to its
 667 regulation of iron metabolism.

668 The effects of EMFs on iron metabolism in neurological diseases

669 Iron is an essential element in neurodevelopment, and research has shown that iron
 670 deficiency anemia can impair central nervous system development [195]. Conversely,
 671 iron accumulation has been closely linked to the pathogenesis of various genetic and
 672 neurodegenerative diseases[196]. Besides, some psychiatric diseases, including
 673 depression, cognitive impairments, schizophrenia, and post-traumatic stress disorder
 674 (PTSD) may also be associated with systemic iron metabolism dysregulation[197].
 675 EMFs have been widely applied for both enhancing nervous system function and
 676 promoting injury repair. TMS, as a non-invasive electromagnetic field based technique,
 677 has been extensively used in the treatment of various neurological disorders[27]. In
 678 addition to the previously mentioned interest in the relationship between EMF
 679 regulation of iron metabolism and the neurobiological safety of EMF exposure, the
 680 therapeutic potential of EMF effects on iron metabolism in neurological disorders has
 681 also been widely explored. The effects of EMFs exposure on iron metabolism in
 682 nervous system are shown in table 1.

683 Neural injury

684 Iron overload can interfere with the recovery process of spinal cord injury and has
 685 been closely linked to neuronal ferroptosis[198]. In recent years, the role of EMFs in
 686 neural injury repair has gained increasing attention. Wincek A., through clinical studies,
 687 found that repetitive transcranial magnetic stimulation (rTMS) can enhance neural
 688 signal transmission within residual spinal cord neurons, thereby promoting motor
 689 control recovery in patients with incomplete spinal cord injury (SCI) [199]. The
 690 relationship between the effects of EMFs on neuronal cells and their regulation of iron
 691 metabolism and ROS is an important research direction in the application of EMFs for
 692 neural injury repair. Dey S et al. found that 2 hours per day 50 Hz, 17.96 μT ELF-
 693 EMFs exposure for 8-week increased iron content, promoted vascular regeneration,
 694 reduced lesion volume and inflammation in the spinal cord injury area of rats[200].
 695 Mesenchymal stem cells (MSCs) have been extensively investigated as a novel cell-

therapeutic solution for neurodegenerative diseases and neural injury due to their ability to differentiate into neuronal-like cells[201]. The differentiation of neural stem cells is accompanied by an increase in FTL expression[202]. 50 Hz, 1 mT ELF-EMF exposure has been shown to promote the neural differentiation of human bone marrow mesenchymal stem cells (hBMSCs) and increase the expression of IRP1, FTH1 and FTL[136, 203, 204]. Notably, ROS levels increased during the astrocytic differentiation of BMSCs under 50 Hz, 1 mT ELF-EMF exposure. FTL is involved in iron storage from the labile iron pool (LIP) and the release of iron from ferritin through electron transfer, thus maintaining the dynamic equilibrium of intracellular LIP and redox balance[205]. The upregulation of FTL expression can induced a mild increase in ROS levels without causing significant oxidative stress damage. Furthermore, studies have shown that both 50 Hz, 1 mT ELF-EMF exposure and its combination with iron-based nanoparticles (NPs) can promote neural differentiation of hBMSCs, which is associated with a mild increase in intracellular ROS levels[115, 116]. Pal A et al. also found that 50 Hz, 17.96 μ T ELF-EMF exposure promoted the repair of spinal cord injury in albino Wistar rats. Moreover, the ELF-EMF combined with iron-based NPs had a synergistically effect on enhancing spinal cord injury repair *in vivo*, and reducing oxidative stress induced by H_2O_2 *in vitro*[206]. Therefore, the upregulation of FTL caused by EMFs could promote neural differentiation of MSCs by inducing a mild increase in intracellular ROS levels, and inhibit oxidative stress damage caused by excessive accumulation of exogenous iron (iron based- NPs) and H_2O_2 .

Neurodegenerative diseases

Neurodegenerative diseases encompass a spectrum of disorders characterized by neuronal death or impaired neuronal function, including Parkinson's disease (PD), Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), and Huntington's disease [207]. Recent studies have revealed a close association between the progression of neurodegenerative diseases and abnormalities in iron metabolism, with different types of these diseases exhibiting distinct iron metabolism characteristics[208]. PD is a neurodegenerative disorder characterized by both motor and non-motor symptoms, resulting from the loss of dopaminergic neuronal function. Iron deposition in substantia nigra pars compacta (SNpc) is a hallmark pathological feature in PD patients, and ferroptosis has been identified as a contributing factor to the progressive loss of dopaminergic neuronal function and cell death [209]. AD is the leading cause of dementia. Studies have shown that brain tissue slices from AD patients typically exhibit higher magnetic iron oxide magnetite (Fe_3O_4) content, and iron deposition in the cortex and hippocampus is a key pathological feature of AD. Iron accumulates in neurons, glia, as well as in A β plaques and neurofibrillary tangles, leading to abnormal expression of A β and phosphorylated tau, which are important triggers for the progression of AD[210, 211]. ALS is a rare neurodegenerative disease characterized by the progressive loss of motor neurons, with iron deposition in motor neurons and glial cells being one of its pathological characteristics[212]. Additionally, increased iron in subcortical structures and the surrounding white matter have been identified as a feature of early HD[213]. Therefore, targeting iron metabolism and ferroptosis has become a major focus in recent research on the treatment of neurodegenerative diseases. Iron chelators and ferroptosis inhibitors have demonstrated therapeutic potential for neurodegenerative diseases in cellular and animal models[214]. However, the iron chelator deferoxamine has been shown to inhibit the progression of AD but not PD in clinical studies[215, 216].

A large number of clinical trials have demonstrated the therapeutic effects of EMFs on neurodegenerative diseases, such as improving motor function in PD patients, enhancing cognitive function in AD patients, and alleviating muscle decline in ALS patients[217-219]. Meanwhile, the regulation of iron metabolism and reactive oxygen species (ROS) in neural cells by EMFs has been shown to involve in counteracting neurodegenerative diseases. Studies have shown that 0.23 T to 0.28 T SMF exposure reduced the expression of the PD biomarker adenosine A(2A) receptor (A(2A)R) in PC12 cells, similar to the effects of the PD drug candidate ZM241385. Furthermore, SMF exposure decreased cAMP levels, nitric oxide production, p44/42 MAPK phosphorylation, cell proliferation, and iron uptake in PC12 cells[220, 221]. Xu et al. demonstrated that 25 Hz rTMS treatment increased the expression of glutathione peroxidase 4 (GPX4) and system Xc-, reduced oxidative stress levels in brain, enhanced cognitive function and augments cerebral activity, and ameliorated AD-like symptoms in SAMP8 mice[101]. Moreover, rTMS decreased the expression of TfR1 and reduced levels of Fe^{2+} , while increased the expression of NRF2 and FTH1. Superoxide dismutase 1 (SOD1) is a key antioxidant enzyme that maintains redox homeostasis, and its dysfunction can result in excessive ROS accumulation. Mutations in SOD1 induced neuronal dysfunction are the causative actors for ALS [222]. Consales et al. found that while 50 Hz, 1 mT ELF-EMF exposure did not significantly decrease the generation of superoxide and H_2O_2 in SOD1^{G93A} mutants SH-SY5Y cells, it reduced the expression of TFR1, IRP1, and MFRN1[137]. Tasset I et al. also found that 60 Hz, 0.7mT TMS treatment increased the expression and nuclear translocation of NRF2 in neuronal cells in Huntington's disease-like rats induced by 3-nitropropionic acid [223]. Weiler M. et al. found that TMS significantly upregulated TfR1 expression in hippocampal cells *ex vivo*, a phenomenon associated with enhanced myelination processes[224]. Additionally, they found that TMS increased the expression of hemoglobin-related genes in the hippocampal cells of young rats but decreased their expression in aged rats. Notably, unlike extracellular hemoglobin, which may induce neuronal damage through oxidative stress and iron accumulation, endogenously expressed hemoglobin in neurons plays a crucial role in maintaining normal mitochondrial function and protecting against oxidative stress-related damage in the brain[225, 226]. Therefore, the relationship between EMFs-mediated regulation of neuronal hemoglobin expression and its potential impact on neurodegenerative diseases remains to be further elucidate. Collectively, these observations and studies suggest that EMFs could improve oxidative stress levels, inhibits ferroptosis in neural cells by regulating iron metabolism, plays a protective role in the nervous system, and suppresses the progression of neurodegenerative diseases. However, some studies suggests that electromagnetic fields could influence the progression of neurodegenerative diseases by modulating neuronal electrical activity, which is independently from iron homeostasis[227, 228]. Consequently, when considering electromagnetic field-based interventions for neurodegenerative disorders, it is essential to monitor not only iron metabolism but also electrophysiological parameters associated with neuronal activity.

Additionally, transcranial magnetic stimulation (TMS) can synergistically enhance its protective effects against neurological diseases when combined with iron-based NPs. Studies have demonstrated that intravenous administration of iron-based NPs enhances TMS-induced motor evoked potential (MEP) and improves the therapeutic effects of low-frequency rTMS (LF-rTMS) on prenatal valproic acid (VPA)-induced autism spectrum disorder (ASD) in rats [58, 135]. Intravenous administration of iron-based NPs enhanced TMS-induced motor evoked potential

(MEP), and therapeutic effects of low-frequency rTMS (LF-rTMS) on prenatal valproic acid (VPA)-induced ASD in rats [141, 229].

The effects of EMFs on iron metabolism in orthopedic diseases

Orthopedic diseases primarily include bone and mineral disorders such as osteoporosis, fractures, and osteogenesis imperfecta, as well as osteoarticular diseases like osteoarthritis (OA), rheumatoid arthritis (RA), and intervertebral disc degeneration (IVDD). The use of EMFs as a therapeutic approach for orthopedic diseases has a history spanning over fifty years[230]. With advancing insights into the pathogenesis and mechanisms underlying orthopedic diseases, iron metabolism and ferroptosis have emerged as key therapeutic targets for these diseases[231, 232]. Consequently, regulating iron metabolism has become a critical focus for enhancing the efficacy of EMF-based treatments in orthopedic diseases.

Bone and mineral disorders

Iron metabolism disorders are closely associated with bone and mineral disorders [231, 233]. On one hand, iron is an essential component of various enzymes involved in collagen synthesis, which is crucial for bone formation[234]. On the other hand, excessive iron could suppress osteoblast mediated bone formation by inhibiting the activation of the Wnt/ β -catenin signaling pathway, and promotes osteoclast differentiation and bone resorption by activating the NF- κ B signaling pathway through the generation of ROS [235, 236]. For instance, long-term transfusion-related systemic iron overload has been implicated in the development of osteoporosis in thalassemia patients and hypophosphataemic osteomalacia [144, 237]. Sickle cell anemia, an inherited Hb disorder disease characterized by low hemoglobin levels and elevated serum ferritin level [238]. Studies found that sickle cell anemia patients have lower bone mass in children, and higher prevalence of osteoporosis[239, 240]. Furthermore, iron accumulation in the body increases with age, especially after menopause in women. Clinical studies have demonstrated a positive correlation between serum ferritin levels and both the rate of bone loss and the occurrence of vertebral fractures in postmenopausal women[241, 242]. The influence of EMFs on bone remodeling is closely associated with the regulation of iron metabolism [4, 243]. Our previous clinical study revealed that, compared to the control group, 90-day MSMF intervention exhibited a greater increase in BMD, accompanied by a more pronounced reduction in serum ferritin levels in postmenopausal osteoporosis patients[104]. As shown in table 2, the effects of EMFs on iron metabolism of cells involved in bone remodeling vary depending on cell types and magnetic field parameters.

During the bone remodeling, bone formation is primarily mediated by osteoblasts, and bone resorption is primarily mediated by osteoclast. Our previous studies found that 0.2 T-0.4 T SMF exposure promoted the recovery of hindlimb unloading (HLU) induced bone loss, increased femoral microstructure and serum bone formation marker OCN levels, whereas decreased the distribution of osteoclasts on femoral bone surface and serum bone resorption marker TRAP-5b levels in mice[244]. Meanwhile, 0.2 T-0.4 T SMF exposure reduced iron content, and promoted osteogenic differentiation while inhibited adipogenic differentiation of BMSCs[245]. 16 T SMF exposure increased the mineralized nodules formation and ALP activity, as well as the expression of osteogenic markers such as Col-1, DMP1, and OCN during osteogenic differentiation of MC3T3-E1 cells. Concurrently, SMF exposure decreased the iron content and TfR1 expression

while increased FPN expression in MC3T3-E1 cells [246]. In contrast, as previously describe, 16 T SMF exposure increased the FPN expression, decreased the expression of FTH1, TfR1, and DMT1, as well as reduced intracellular iron content in RANKL-induced RAW264.7 cells [131]. Additionally, 16 T SMF inhibited RANKL-induced osteoclast differentiation. Furthermore, studies showed that 1 T-2 T SMF exposure inhibited HLU-induced bone loss and osteoclast activation in mice, reduced iron content in bone and osteoclasts, and decreased the FTH1 expression during RAW264.7 cells osteoclastic differentiation [106]. Collectively, these findings suggest that SMF exposure reduces iron content in both osteoblasts and osteoclasts, although its effects on the expression of iron metabolism-related proteins differ between cell types. Given that excess iron inhibits osteoblast differentiation but promotes osteoclast differentiation, SMFs appear to prevent bone loss by simultaneously promoting bone formation and suppressing bone resorption. Osteocytes, as the primary regulatory cells in bone tissue, modulate the functions of osteoblasts and osteoclasts through the secretion of various cytokines. Yang J et al found that 16 T SMF exposure increased cell viability and intracellular iron content in MLO-Y4 osteocyte-like cells. Furthermore, 16 T SMF increased the expression of the bone remodeling mediator PGE2 and the bone resorption promoter RANKL in bone cells while reducing the expression of the bone formation inhibitor sclerostin in MLO-Y4 cells [247]. However, the regulatory effect of osteocytes on osteoclasts mainly depends on the ratio of RANKL/osteoprotegerin (OPG). Further studies are needed to assess the levels and ratios of RANKL and OPG secreted by osteocytes to elucidate their role in bone resorption under SMF exposure. Additionally, the promotion of cell viability and ALP expression induced by 16 T SMF exposure was mitigated by FAC. However, the 16 T SMF exposure induced increase in NO secretion was enhanced by both DFO and FAC. This further confirms that the regulation of osteocyte morphology and function by SMF is related to the changes in iron metabolism. Interestingly, the effects of EMFs on iron metabolism in bone remodeling do not appear to be static. Rather, they exhibit a context-dependent nature, with varying effects on iron metabolism tailored to meet the requirements for correcting imbalances in bone remodeling.

Osteoporosis is a common complication of diabetes. Our previous study found that the serum ferritin has been increased, whereas tibial total iron content was decreased in streptozotocin induced type 1 diabetic mice [248]. Meanwhile, 0.4-0.7 T SMF exposure inhibited bone loss, increased bone iron content, and upregulated the expression of FPN, TfR1, and FTH1 in type 1 diabetic mice. Moreover, 0.4 T-0.7 T SMF enhanced bone turnover in type 1 diabetic mice, as well as promoted both osteoblast and osteoclast differentiation under high-glucose conditions in vitro. Furthermore, our previous study found that 0.05 T-0.5 T SMF exposure promoted fracture healing, reduced iron content at the bone callus site, decreased serum ferritin levels, and increased serum hepcidin levels in mice [134]. Notably, 0.05 T-0.5 T SMF exposure not only enhanced bone formation but also facilitated the transition from cartilage callus to hard callus. The transition from cartilage callus to hard callus not only not only conventional osteoblast-mediated bone formation and osteoclast-mediated bone resorption but also processes such as the chondrogenic differentiation of MSCs, apoptosis of chondrocytes, and chondrocyte-to-osteoblast transdifferentiation [249]. These results suggest that SMFs could regulate functionality and fate of chondrocytes by modulating iron metabolism. Time-varying magnetic fields have also been shown to regulate bone remodeling by modulating iron metabolism. Wang Q et al. found that PEMF promoted osteogenic differentiation and increased the NRF2 expression in amniotic epithelial cells [250].

Melatonin has garnered significant attention in the study of iron accumulation and iron overload-related diseases due to its unique structure, which allows it to exhibit both iron-chelating and antioxidant properties. Huang et al. found that the PEMF enhanced the anti-bone loss effect of melatonin in OVX mice[251, 252].

In contrast, the absence of the GMF could disrupt the balance of bone remodeling by modulating iron metabolism. Artificial HyMF environments are widely used to evaluate the biological effects of absence of geomagnetic field. Our previous studies found that the HyMF exposure did not directly induce bone loss but exacerbated HLU-induced deterioration of bone microstructure, reductions in mechanical performance and bone formation, and increased bone resorption in rats and mice [253, 254]. Meanwhile, HyMF increased serum ferritin, liver iron content, and bone iron content in HLU rats and mice. Furthermore, HyMF inhibited the recovery of femoral microstructure and mechanical properties of in HLU-pretreated mice, which was attenuated by iron chelator DFO [105]. In addition, HyMF increased the intracellular iron content and inhibited mineralized nodules formation in MC3T3-E1 cells during osteogenic differentiation in vitro[255]. These findings indicate that HyMF exacerbates inducible bone loss by promoting iron accumulation.

EMFs can also be used in combination with iron preparations and iron metabolism regulators to regulate bone remodeling. The Ferumoxytol, an iron-based NP and FDA approved iron supplement, has been observed alleviated HLU induced bone loss by inhibiting osteoclast differentiation and bone resorption. Further investigations revealed that the combination of 1–2 T SMF and Ferumoxytol inhibited the activation of NF- κ B and MAPK pathways during osteoclast differentiation by reducing intracellular iron content and reactive oxygen species (ROS), exhibiting a synergistic anti-bone loss effect in vivo [106]. The combination of 0.2 T SMF and iron-based NPs promoted osteoblast differentiation and induced apoptosis in osteoclasts in vitro[142].

Osteoarticular diseases

Iron metabolism disorders are also implicated in the onset and progression of osteoarticular diseases, including OA, RA, and IVDD[232]. Many clinical studies have reported that age-related and post-traumatic osteoarthritis were usually accompanied by iron deposition at the site of pathology[256]. Meanwhile, the incidence of knee OA and IVDD is significantly higher in individuals with hemochromatosis compared to the general population[257, 258]. Furthermore, studies have showed that iron overload disrupted the normal function of chondrocytes and induced ferroptosis, while interventions such as iron chelator DFO and ferroptosis specific inhibitor ferrostatin-1 suppressed the progression of OA [259-261]. In addition, iron deficiency anemia is the most common haematological manifestation of patients with RA (30-60%), and iron deficiency itself may accelerate the progression of IVDD [262-264].

Numerous studies have demonstrated that EMFs alleviate OA, RA, and IVDD by regulating the differentiation and the physiological functions of chondrocytes and intervertebral disc cells[265, 266]. Although direct evidence of EMFs modulating the progression of osteoarticular diseases through iron metabolism regulation is currently lacking, several studies have reported changes in iron metabolism and ROS levels during EMF treatments for these conditions[117]. Bi et al found that RMFs alleviated of RA, and increased serum iron and transferrin levels, as well as total iron-binding capacity in rats[267]. Besides, Lv Z et al found the combination of 1 MHz RF-EMF

and iron-based NPs-TRPV1 increased the FTH1 expression, decreased the NCOA4 expression, and inhibited tert-butyl hydroperoxide (TBHP)-induced ferroptosis in chondrocyte in vitro. Meanwhile, the 1 MHz EMF and iron-based NPs-TRPV1 treatment attenuated osteoarthritis progression in mice[140]. Therefore, iron metabolism represents a crucial research target in the study of EMF-based therapies for osteoarticular diseases and should not be overlooked.

The effects of EMFs on iron metabolism in diabetes

Iron plays a critical role in glucose and lipid metabolism through pathways such as regulating metabolic rates, gluconeogenesis, insulin action, and adipocyte signaling[268]. Serum ferritin levels are correlated with an increased risk of type 2 diabetes (T2D), and iron overload is associated with decreased insulin secretion, insulin resistance, and increased hepatic gluconeogenesis in type 2 diabetes mellitus (T2DM)[269]. Blood transfusions induced iron overload has been shown to increase the incidence of diabetes in β -thalassemia patients. Furthermore, phlebotomy has been reported to improve insulin secretion in diabetes patients, Iron chelators and ferroptosis inhibitors have also been shown to have therapeutic effects in alleviating diabetes and its associated complications[270]. EMF therapy has demonstrated efficacy in the clinical treatment of diabetic complications, such as diabetic peripheral neuropathy and diabetic foot ulcers[271]. In recent years, growing attention has been given to the relationship between the effects of EMFs on diabetes progression and their role in regulating iron metabolism. Yu B et al found that the downward 100 mT SMF exposure for 12 consecutive weeks reduced iron levels and ROS in pancreatic cells, and prevented the development of high-fat diet (HFD)-induced T2D and ameliorated related symptoms[102]. Meanwhile, the combined exposure to 3 mT SMF and 7 kV/m electric fields for 30 days was shown to inhibit the progression of type 2 diabetes by reducing intracellular ROS level [272]. These results proved the potential of EMFs in diabetes treatment by regulating iron metabolism. However, some studies have also reported that extreme SMFs exposure may exacerbate diabetes and related tissue damage. High gradient (up to 55.5 T/m) 1.0 T-8.6 T SMFs exposure elevated glycosylated serum protein and blood glucose levels, and exacerbated the spleen, hepatic, and renal tissue impairment in both T1D and T2D mice. Moreover, gradient SMFs did not significantly alter iron levels in serum, while increased the levels of oxidative stress in kidney tissue of diabetic mice[107]. These findings suggest that the effects of SMF exposure on iron metabolism and diabetes are parameter-specific. Simply increasing the intensity and gradient of SMFs could lead to adverse reactions, underscoring the importance of optimizing exposure parameters in potential therapeutic applications. Overall, EMFs can influence the physiological function of pancreatic cells and the body's glucose metabolism by regulating iron metabolism, offering a new approach for the physical treatment of diabetes.

The effects of EMFs on iron metabolism in liver injury

Liver is one of the primary iron storage organs and serves as the regulator of systemic iron metabolism. Studies have shown that the changes of external magnetic field environments can regulate systemic iron metabolism by altering liver iron content. Our previous studies found that 300nT HyMF exposure increased liver iron content in mice during both HLU and the reloading process[105, 253]. Drago M et al. reported that 16 mT SMF with different orientation exposure for 28 days reduced liver iron

content in mice[273]. Similarly, our earlier research found that 0.05 T-0.5T SMF exposure reduced liver iron content in mice with fractures[134]. Moreover, 2 T-4 T and 6 T-8 T SMF exposure for 28 days had no significant effect on liver iron content, whereas 10 T-12T SMF exposure increased liver iron content in mice[20]. These findings demonstrate that the effects of EMFs on liver iron metabolism display a distinct “window effect,” wherein specific magnetic field parameters determine their regulatory outcomes. In addition, certain EMFs exposure showed the protective potential against liver damage caused by iron metabolism disorders. Dietary iron overload has been found to decrease hepatic mitochondrial oxidative phosphorylation and exacerbate mitochondrial dysfunction induced by oxidative stress in mice[274]. Meanwhile, some patients with alcoholic liver disease exhibit disruptions in iron metabolism[275]. Ethanol suppresses the hepcidin expression in hepatocytes, facilitating duodenum iron absorbed, while simultaneously promoting the expression of TfR in hepatocytes, thereby increasing hepatic iron uptake[276, 277]. Excessive iron accumulation in the liver can elevate oxidative stress levels within hepatocytes, thereby aggravating liver damage and potentially triggering iron-induced ferroptosis[278]. Zhang X et al found the 0.1 T~0.2 T and 3 T SMFs exposure reduced alcohol-induced inflammation, ROS levels, and oxidative stress in the liver of mice[138, 279]. Similarly, Lv et al. found that 0.6 T SMF exposure reduced hepatic iron content in obesity and diabetes mice, and balanced hepatic redox status via the regulation of MAPKs/Nrf2/HO-1 antioxidant pathways, and mitigated liver injury associated with obesity and diabetes [280]. However, some studies have described that t that the decrease in liver iron content under EMF exposure is associated with increased iron release from the liver into the bloodstream.[281]. Therefore, although EMFs hold considerable potential for modulating hepatic iron metabolism and preventing associated liver damage, it is crucial to consider their broader effects on iron metabolism in other tissues when designing therapeutic strategies.

The effects of EMFs on iron metabolism in cancer

Although several studies have suggested the potential carcinogenicity of EMFs, many others have demonstrated therapeutic potential of EMFs in combating cancers[282-284]. Abnormal iron metabolism is a hallmark of cancer cells, and the targeted regulation of iron metabolism has become a focal point in cancer treatment. Numerous studies have shown that the regulation of iron metabolism by EMFs is closely associated with its effects on cancer progression, which not limited to standalone treatments, but also extend to combination therapies involving chemotherapy drugs or iron-based NPs (Table 3).

Iron metabolism and cancer

The majority of malignant cancer cells are characterized by dysregulated iron metabolism, where tumor growth, proliferation, invasion, and metastasis require elevated levels of iron [285]. Intracellular iron contributes to the formation of DNA strand breaks and oxidizing DNA bases, as well as generation of intracellular free radicals, further inducing genetic mutations. Consequently, the abnormally elevated intracellular iron is carries a risk for carcinogenesis[286]. The high expression of iron uptake-related genes, such as TFR1 and DMT1, as well as iron storage-related genes like FTH1, have been reported in various cancers, including hepatocellular carcinoma, lung cancer, breast cancer, colorectal cancer, and pancreatic cancer [287-290].

Meanwhile, reduced iron efflux also contributes to the maintenance of elevated intracellular iron levels in cancer cells. Decreased expression of FPN has been observed in cell lines and human samples of breast, lung, and prostate cancers[291-294]. Besides, the low FPN expression is strongly correlated with poor pathology and prognosis in cancers. On one hand, inhibiting iron uptake and facilitating iron efflux have shown promise in suppressing cancer progression. For example, iron chelators and the decreased local hepcidin expression contribute to improving cancer prognosis. On the other hand, the "iron addiction" of cancer cells induced the increasing of intracellular ROS, renders these cells more vulnerable to redox imbalances, renders it more vulnerable to redox imbalance. This vulnerability offers novel therapeutic targets for selectively eliminating cancer cells, such as through ferroptosis[37].

The relationship between the effects of EMFs on iron metabolism and cancer progression

EMFs, as a standalone or adjunctive therapy, have demonstrated efficacy in the clinical treatment of various cancers, such as improving the quality of life for patients with hepatocellular carcinoma and advanced lung cancer[284, 295]. However, the effects of EMFs on cancer-related iron metabolism are diverse, with studies highlighting their dual roles in modulating intracellular iron levels. Many studies have demonstrated that EMFs exert anti-cancer effects by reducing intracellular iron content. Hajipour Verdom B et al. found that 10 mT SMF exposure inhibited the proliferation, and decreased intracellular iron content in MCF-7 and HFF cells [118]. Interestingly, that the SMF exposure increased intracellular ROS levels in MCF-7 and HFF cells, although intracellular iron, the important source of ROS generation, was significantly decreased. Ren J et al. found that the 7.5 Hz, 0.4 T ELF-EMF inhibited the LCC cells proliferation in vitro and tumor growth in vivo by arresting the cell cycle at the G1 phase and promoting p53 expression. Meanwhile, ELF-EMF exposure reduced iron content, and decreased the TfR1 and FTH1 expression in both LCC cells in vitro and in lewis lung cancer murine model in vivo. Moreover, the anti-lung cancer effects of the ELF-EMF were mitigated by FAC[108]. Iron is essential for maintaining the activity of ribonucleotide reductase and DNA polymerase. The S phase and G2 phase of the cell cycle are critical stages for DNA synthesis and repair during mitosis. Therefore, the inhibitory effect of 7.5 Hz, 0.4 T ELF-EMF on cell proliferation may be linked to suppressed DNA synthesis due to cellular iron deficiency.

Nevertheless, there are also many studies have shown that EMFs can suppress cancer progression by regulating the expression of iron metabolism-related genes and increasing intracellular iron levels. Our previous study found that 12 T SMF exposure inhibited proliferation, and increased the intracellular iron content, LIP and ROS levels in MNNG/HOS, U-2 OS, and MG63 osteosarcoma cell lines *in vitro* [103]. The anti-osteosarcoma effects of 12 T SMF were attenuated by antioxidants (NAC) and iron chelators (DFO) but enhanced by FAC. This indicates that the primary mechanism of 12 T SMF's anti-osteosarcoma effects lies in the disruption of redox homeostasis due to increased intracellular iron and ROS. Meanwhile, 12 T SMF exposure increased the expression of FTH1 and DMT1 without significantly affecting the expression of TfR1 and FPN in osteosarcoma cells. These findings suggest that increased LIP under 12 T SMF exposure may result from enhanced uptake of NTBI, which is primarily mediated by DMT1, and that FTH1 upregulation reflects a protective response to the excessive accumulation of intracellular free iron. Lai HC et al. also reported that the 134 KHz RF-

EMFs exposure inhibited the proliferation of Molt-4, BT474, and HepG2 cells in vitro, with the effects was suppressed by iron chelator DFO and ROS scavenger N-tert-butyl-alpha-phenylnitron (PBN) [109]. Accordingly, the anti-cancer cell effects of RF-EMFs may involve promoting iron-related ROS production and disrupting the cellular redox balance. The excessive accumulation of ROS generated by intracellular iron through the Fenton reaction is a key inducer of ferroptosis. Furthermore, EMFs have been indicated could induce ferroptosis in cancer cells. Yuan LQ et al. found that the 50 Hz, 5.1 mT ELF-EMF exposure increased intracellular ROS and inhibited the proliferation of G401 and A549 cells, with the effects could be attenuated by the ferroptosis inhibitor, ferrostatin-1[119]. These results suggest that utilizing electromagnetic fields to regulate iron metabolism and induce ferroptosis in cancer cells holds potential as a direction for cancer treatment research.

Cancer stem cells (CSCs), a subpopulation of cancer cells, possess remarkable proliferative, self-renewal, and differentiation capability. CSCs play pivotal role in cancer progression and metastasis, making it garnered significant attention as a therapeutic focus of drug resistance of cancer[296]. Compared to general cancer cells, CSCs have higher LIP and ferritin levels. Meanwhile, CSCs often exhibit enhanced redox adaptation and regulatory capabilities, whereas general cancer cells tend to experience fragile redox balance due to increased intracellular iron levels [297]. Zhao et al. found that 0.2-0.4 T SMF exposure increased LIP and intracellular ROS in K7M2 and MG63 osteosarcoma stem cells by promoting NCOA4 mediated ferritinophagy. Meanwhile, the SMF improved the self-renewal ability of osteosarcoma stem cells [55]. It suggests that changes in CSC-related markers should not be overlooked when using EMFs to regulate iron metabolism for cancer treatment. Therefore, additional combination approaches may be necessary to effectively harness EMFs in modulating iron metabolism-induced ROS accumulation, thereby targeting and eliminating CSCs.

Combined effects of EMFs, chemotherapeutic drugs, and iron-based nanoparticles on iron metabolism in cancer

The combination of EMFs with chemotherapeutic drugs has been widely studied in cancer treatment. In recent years, with the deepening understanding of the biological effects of EMFs and the increasing research on ferroptosis- related cancer treatment, the interplay between the effects of EMFs and chemotherapeutic drugs on iron metabolism in cancer cells has attracted significant attention. Cisplatin, a conventional chemotherapy drug, has been found to reduce intracellular iron levels in cancer cells. Furthermore, various studies have demonstrated that cisplatin acts as a ferroptosis inducer[298, 299]. Several EMFs have been shown to enhance the anti-cancer effects of cisplatin both in vitro and in vivo[300-304]. Doxorubicin, another broad-spectrum anti-cancer drug, has also been studied in combination with EMFs. Hajipour Verdom B et al. found that the combination of 10 mT SMF and doxorubicin synergistically reduced intracellular iron content and increased intracellular ROS levels in MCF7 cells[118]. Therefore, the utilization of regulatory effect of EMFs on iron metabolism holds significant potential as an adjunctive therapy in cancer chemotherapy

Due to inherent electromagnetic properties of iron-based NPs, which can be locally accumulated by EMFs. Studies have indicated that EMFs enhance the targeted aggregation, the binding to the cell membrane, and internalization of iron-based NPs in vitro and in vivo[305-307]. Meanwhile, various types of exogenous EMFs can alter the

iron release rate of iron-based NPs. Consequently, extensive studies have been conducted on the synergistic effect of EMFs and iron-based NPs in inducing ferroptosis in cancer cells. Magnetic hyperthermia therapy (MHT) refers to a therapeutic approach that utilizes the heat generated by magnetic nanoparticles under external time-vary magnetic fields to increase the temperature in the target area. MHT has gained significant attention in tumor treatment due to its non-invasive property, excellent tissue penetration, and demonstrated remarkable anti-tumor efficacy[308]. Iron-based NPs are the most commonly used magnetic NPs in MHT. Sadhukha et al. found that 386 kHz, 7.56 mT EMF in combination with iron-based NPs effectively reduced the proportion of cancer stem cells subpopulations in A549 and MDA-MB-231 cells [309]. Meanwhile, compared to conventional heat therapy established by water bath heating, MHT increased intracellular ROS levels in a time-dependent manner. The heating effect of EMF exposure, along with its interaction with iron-based NPs, improved the sensitivity of cells to oxidative stress, which has been associated with changes in iron metabolism and decreased GPX4 expression[310]. It has reported that during MHT, the EMFs interact with intracellular NPs, accelerating the glutathione consumption mediated by iron and facilitating the iron-catalyzed generation of $\cdot\text{OH}$, which induces oxidative damage and trigger ferroptosis in cancer cells[139]. Li ZF et al. found that compared to Fe_3O_4 NPs treatment alone, the MHT by combination with EMFs inhibited proliferation and migration of HCC-70 cells and suppressed the growth of triple-negative breast cancer (TNBC) in mice. Furthermore, the MHT increased apoptosis levels, and decreased the expression of NRF2 and FTH1 of TNBC cells both in vitro and in vivo[311]. Additionally, the GPX4 expression was significantly decreased, suggesting that MHT induced ferroptosis in TNBC. Ji et al. found that the 30 min, 25 W microwave exposure promoted the iron releases from NPs and induced lipid peroxidation, leading to ferroptosis *in vitro* and *in vivo*[143]. EMFs can also induce ferroptosis in cancer cells by altering the configuration of nanoparticles, enhancing their chemical activity. Recently, some iron-based NPs with unique structural characteristics have been found to exhibit intrinsic peroxidase (POD) or oxidase (OXD)-like activities, catalyzing the generation of intracellular ROS, and referred to as magnetic nanozymes[312]. Studies have shown that EMFs can enhance the ferroptosis-inducing effect of magnetic nanozymes[313]. Yuan et al. reported that the catalytic velocity, Michaelis constant, and catalytic efficiency marker K_{cat}/K_M value of nanozyme under alternating magnetic fields exposure were significantly elevated with increasing magnetic field intensity ranging from 0 to 350 μT [314]. This effect was associated with EMFs exposure promoting electron transfer and increasing the $\text{Fe}^{2+}/\text{Fe}^{3+}$ ratio in nanozymes. They also found that alternating magnetic fields promoted ferroptosis induced by the combined treatment of nanozymes with Xenon lamp in HeLa and MCF-7 cells, and suppressed tumor growth in HeLa-tumor-bearing mice. Moreover, EMFs can synergistically regulate iron metabolism in conjunction with iron-based NPs and facilitate the release of carried drugs, thereby augmenting their anti-cancer effects. Orel V et al. found that compared to conventional doxorubicin treatment, the combination of SMF and RF-EMFs inductive hyperthermia below 40°C with doxorubicin-loaded iron-based NPs demonstrated superior efficacy in inhibiting lung cancer growth and metastasis in mice. Meanwhile, RFH decreased the activity of FeS-protein electron transport chains in mitochondria[315]. The anti-cancer effect of this combined treatment may be attributed to its regulation on iron metabolism in mitochondrion, specifically inhibiting electron transfer in mitochondrial iron-sulfur proteins and increasing in non-heme iron complexes with nitric oxide.

1168 **Conclusion and perspective**

1169 EMFs have been widely applied as a non-invasive physical alternative or
1170 adjunctive therapy in translational medicine. The regulation of iron metabolism by
1171 EMFs is a crucial mechanism underlying their biological effects and plays a significant
1172 role in their translational applications. On one hand, iron metabolism-related indicators
1173 can be used to evaluate the biological safety of EMFs. On the other hand, the effects of
1174 EMFs on iron metabolism have potential applications in the research and treatment of
1175 various diseases, including immunoregulation, cardiovascular diseases, neurological
1176 diseases, orthopedic diseases, diabetes, liver injury, and cancer. Moreover, the
1177 synergistic regulation of iron metabolism through the combination of EMFs with
1178 drugs—particularly iron-based NPs—has notably enhanced the potential of EMFs in
1179 the biomedical field. However, conflicting results in many studies regarding the effects
1180 of EMFs on iron metabolism make it challenging to systematically summarize the
1181 regulatory patterns of EMFs on iron metabolism. Despite these inconsistencies, several
1182 general characteristics of EMF-mediated regulation of iron metabolism can still be
1183 summarized. First, the effects of EMFs on iron metabolism vary depending on the
1184 properties of the EMFs (such as intensity, gradient, frequency, etc.) and exposure time
1185 [17]. Additionally, the effects of EMFs on iron metabolism appear to exhibit a
1186 biological "window". It has been reported that the biological effects induced by EMFs
1187 of specific intensities, frequencies, and exposure durations within this "window" may
1188 differ significantly from those outside it [123]. Furthermore, the regulation of iron
1189 metabolism by EMFs also shows significant tissue- and cell-type specificity. Compared
1190 to changes in biochemical indicators, biophysical mechanisms are typically used to
1191 provide a deeper explanation of the biological effects and patterns of EMFs. In this
1192 review, we have summarized several potential biophysical mechanisms through which
1193 EMFs regulate iron metabolism, aiming to better understand the underlying reasons for
1194 the complex regulatory characteristics of EMFs on iron metabolism, and to provide
1195 research insights for utilizing EMFs in the modulation of iron metabolism in the future.
1196 Furthermore, the descriptions of EMFs parameters and exposure forms in many studies
1197 are often vague, which limits the comparability of results across different studies.
1198 Therefore, more precise descriptions of EMF parameters and exposure methods are
1199 needed in future research on the effects of EMFs on iron metabolism and related
1200 diseases. We expect that with extensive and in-depth studies on the effects and
1201 mechanisms of EMFs in iron metabolism, the scope of EMF applications in disease
1202 prevention and treatment is likely to expand.

1203 **Declaration of competing interest**

1204 No potential conflict of interest was reported by the authors.

1205 **Acknowledgments**

1206 This work was supported by the National Natural Science Foundation of China
1207 (52037007), Guangdong Basic and Applied Basic Research Foundation
1208 (2022A1515110171), and the Shenzhen Science and Technology program
1209 (JCYJ20230807144159004).

References

1. Chen, E., et al., *The biological effects of geomagnetic field exhibit an important potential for cancer and vascular diseases*. Cell Biol Int, 2022. **46**(6): p. 878-882.
2. Markov, M.S., *Magnetic field therapy: a review*. Electromagn Biol Med, 2007. **26**(1): p. 1-23.
3. Zhang, G., et al., *The effect of magnetic fields on tumor occurrence and progression: Recent advances*. Prog Biophys Mol Biol, 2023. **179**: p. 38-50.
4. Yang, J., et al., *Evidence of the static magnetic field effects on bone-related diseases and bone cells*. Prog Biophys Mol Biol, 2023. **177**: p. 168-180.
5. Soltani, D., et al., *Electromagnetic field therapy in cardiovascular diseases: A review of patents, clinically effective devices, and mechanism of therapeutic effects*. Trends Cardiovasc Med, 2023. **33**(2): p. 72-78.
6. Riancho, J., et al., *The role of magnetic fields in neurodegenerative diseases*. Int J Biometeorol, 2021. **65**(1): p. 107-117.
7. Nairz, M. and G. Weiss, *Iron in health and disease*. Mol Aspects Med, 2020. **75**: p. 100906.
8. Katsarou, A. and K. Pantopoulos, *Basics and principles of cellular and systemic iron homeostasis*. Mol Aspects Med, 2020. **75**: p. 100866.
9. Choorapoikayil, S. and P. Meybohm, *Iron deficiency: effects beyond anaemia?* Lancet Haematol, 2022. **9**(7): p. e466-e468.
10. Kosman, D.J., *Redox cycling in iron uptake, efflux, and trafficking*. J Biol Chem, 2010. **285**(35): p. 26729-26735.
11. Hsu, C.C., et al., *Iron overload disorders*. Hepatol Commun, 2022. **6**(8): p. 1842-1854.
12. Stockwell, B.R., *Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications*. Cell, 2022. **185**(14): p. 2401-2421.
13. Wang, X., et al., *Zooming in and out of ferroptosis in human disease*. Front Med, 2023. **17**(2): p. 173-206.
14. Duda, D., J. Grzesik, and K. Pawlicki, *Changes in liver and kidney concentration of copper, manganese, cobalt and iron in rats exposed to static and low-frequency (50 Hz) magnetic fields*. J Trace Elem Electrolytes Health Dis, 1991. **5**(3): p. 181-6.
15. Tota, M., et al., *Cellular and Molecular Effects of Magnetic Fields*. Int J Mol Sci, 2024. **25**(16).
16. Wang, H. and X. Zhang, *Magnetic Fields and Reactive Oxygen Species*. Int J Mol Sci, 2017. **18**(10).
17. Zhen, C., et al., *Electromagnetic fields regulate iron metabolism in living organisms: A review of effects and mechanism*. Prog Biophys Mol Biol, 2024. **188**: p. 43-54.
18. Wang, S., et al., *Iron and magnetic: new research direction of the ferroptosis-based cancer therapy*. Am J Cancer Res, 2018. **8**(10): p. 1933-1946.
19. Santos, L.F., A.S. Silva, and J.F. Mano, *Magnetic-Based Strategies for Regenerative Medicine and Tissue Engineering*. Adv Healthc Mater, 2023. **12**(25): p. e2300605.
20. Wang, S., et al., *Effect of High Static Magnetic Field (2 T-12 T) Exposure on the Mineral Element Content in Mice*. Biol Trace Elem Res, 2021. **199**(9): p. 3416-3422.

- 1249 21. Burchard, J.F., D.H. Nguyen, and E. Block, *Macro- and trace element concentrations in blood*
 1250 *plasma and cerebrospinal fluid of dairy cows exposed to electric and magnetic fields.*
 1251 Bioelectromagnetics, 1999. **20**(6): p. 358-64.
- 1252 22. Pilla, A.A., *Mechanisms and therapeutic applications of time-varying and static magnetic fields.*
 1253 Biological and medical aspects of electromagnetic fields, 2007. **3**.
- 1254 23. Zhang, J., et al., *Effects of static magnetic fields on bone microstructure and mechanical*
 1255 *properties in mice.* Electromagn Biol Med, 2018. **37**(2): p. 76-83.
- 1256 24. Sarimov, R.M., D.A. Serov, and S.V. Gudkov, *Hypomagnetic Conditions and Their Biological*
 1257 *Action (Review).* Biology (Basel), 2023. **12**(12).
- 1258 25. Zhou, C. and J. Tang, *Analysis on the operation parameters of cooling water system in 45.22 T*
 1259 *hybrid magnet experiment.* Case Studies in Thermal Engineering, 2023. **44**: p. 102868.
- 1260 26. Organization, W.H., *Environmental Health Criteria 238: Extremely Low Frequency Fields.*
 1261 World Health Org., Geneva, Switzerland 2007, 2007.
- 1262 27. Rawji, V., et al., *On the Use of TMS to Investigate the Pathophysiology of Neurodegenerative*
 1263 *Diseases.* Front Neurol, 2020. **11**: p. 584664.
- 1264 28. Wei, Y. and X. Wang, *Biological effects of rotating magnetic field: A review from 1969 to 2021.*
 1265 Prog Biophys Mol Biol, 2023. **178**: p. 103-115.
- 1266 29. Davidson, B., et al., *Neuromodulation techniques - From non-invasive brain stimulation to deep*
 1267 *brain stimulation.* Neurotherapeutics, 2024. **21**(3): p. e00330.
- 1268 30. El-Maleky, N.F. and R.H. Ebrahim, *Effects of exposure to electromagnetic field from mobile*
 1269 *phone on serum hepcidin and iron status in male albino rats.* Electromagn Biol Med, 2019.
 1270 **38**(1): p. 66-73.
- 1271 31. Kopani, M., et al., *Iron deposition in rabbit cerebellum after exposure to generated and mobile*
 1272 *GSM electromagnetic fields.* Bratisl Lek Listy, 2017. **118**(10): p. 575-579.
- 1273 32. Andreini, C., et al., *The human iron-proteome.* Metallomics, 2018. **10**(9): p. 1223-1231.
- 1274 33. Teh, M.R., A.E. Armitage, and H. Drakesmith, *Why cells need iron: a compendium of iron*
 1275 *utilisation.* Trends Endocrinol Metab, 2024.
- 1276 34. Ru, Q., et al., *Iron homeostasis and ferroptosis in human diseases: mechanisms and therapeutic*
 1277 *prospects.* Signal Transduct Target Ther, 2024. **9**(1): p. 271.
- 1278 35. Muckenthaler, M.U., et al., *A Red Carpet for Iron Metabolism.* Cell, 2017. **168**(3): p. 344-361.
- 1279 36. Nemeth, E. and T. Ganz, *Hepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis.*
 1280 Int J Mol Sci, 2021. **22**(12).
- 1281 37. Galy, B., M. Conrad, and M. Muckenthaler, *Mechanisms controlling cellular and systemic iron*
 1282 *homeostasis.* Nat Rev Mol Cell Biol, 2024. **25**(2): p. 133-155.
- 1283 38. Crielgaard, B.J., T. Lammers, and S. Rivella, *Targeting iron metabolism in drug discovery and*
 1284 *delivery.* Nat Rev Drug Discov, 2017. **16**(6): p. 400-423.
- 1285 39. Ohshima, T., et al., *NCOA4 drives ferritin phase separation to facilitate macroferritinophagy*
 1286 *and microferritinophagy.* J Cell Biol, 2022. **221**(10).
- 1287 40. Cardona, C.J. and M.R. Montgomery, *Iron regulatory proteins: players or pawns in ferroptosis*
 1288 *and cancer?* Front Mol Biosci, 2023. **10**: p. 1229710.

- 1289 41. Dong, Y., et al., *Nrf2 activators for the treatment of rare iron overload diseases: From bench*
1290 *to bedside*. Redox Biol, 2025. **81**: p. 103551.
- 1291 42. Ma, Z., et al., *Nrf2 protects against cartilage endplate degeneration through inhibiting*
1292 *NCOA4-mediated ferritinophagy*. Int J Mol Med, 2024. **53**(2).
- 1293 43. Yan, R., et al., *NRF2, a Superstar of Ferroptosis*. Antioxidants (Basel), 2023. **12**(9).
- 1294 44. Dixon, S.J. and J.A. Olzmann, *The cell biology of ferroptosis*. Nat Rev Mol Cell Biol, 2024.
1295 **25**(6): p. 424-442.
- 1296 45. Conrad, M. and D.A. Pratt, *The chemical basis of ferroptosis*. Nat Chem Biol, 2019. **15**(12): p.
1297 1137-1147.
- 1298 46. Dai, E., et al., *A guideline on the molecular ecosystem regulating ferroptosis*. Nat Cell Biol,
1299 2024. **26**(9): p. 1447-1457.
- 1300 47. Bren, K.L., R. Eisenberg, and H.B. Gray, *Discovery of the magnetic behavior of hemoglobin:*
1301 *A beginning of bioinorganic chemistry*. Proc Natl Acad Sci U S A, 2015. **112**(43): p. 13123-7.
- 1302 48. Okazaki, M., N. Maeda, and T. Shiga, *Effects of an inhomogeneous magnetic field on flowing*
1303 *erythrocytes*. Eur Biophys J, 1987. **14**(3): p. 139-45.
- 1304 49. Zablotskii, V., T. Polyakova, and A. Dejneka, *Effects of High Magnetic Fields on the Diffusion*
1305 *of Biologically Active Molecules*. Cells, 2021. **11**(1).
- 1306 50. Sudarev, V.V., et al., *Ferritin self-assembly, structure, function, and biotechnological*
1307 *applications*. Int J Biol Macromol, 2023. **224**: p. 319-343.
- 1308 51. Cespedes, O. and S. Ueno, *Effects of radio frequency magnetic fields on iron release from cage*
1309 *proteins*. Bioelectromagnetics, 2009. **30**(5): p. 336-42.
- 1310 52. Cespedes, O., et al., *Radio frequency magnetic field effects on molecular dynamics and iron*
1311 *uptake in cage proteins*. Bioelectromagnetics, 2010. **31**(4): p. 311-7.
- 1312 53. Hernandez-Morales, M., et al., *Lipid Oxidation Induced by RF Waves and Mediated by Ferritin*
1313 *Iron Causes Activation of Ferritin-Tagged Ion Channels*. Cell Rep, 2020. **30**(10): p. 3250-3260
1314 e7.
- 1315 54. Chen, C., et al., *Reactive Oxygen Species Activate a Ferritin-Linked TRPV4 Channel under a*
1316 *Static Magnetic Field*. ACS Chem Biol, 2024. **19**(5): p. 1151-1160.
- 1317 55. Zhao, B., et al., *Static Magnetic Field (0.2-0.4 T) Stimulates the Self-Renewal Ability of*
1318 *Osteosarcoma Stem Cells Through Autophagic Degradation of Ferritin*. Bioelectromagnetics,
1319 2021. **42**(5): p. 371-383.
- 1320 56. Zhang, J., et al., *On the evolutionary trail of MagRs*. Zool Res, 2024. **45**(4): p. 821-830.
- 1321 57. Wei, M., et al., *Filamentous morphology engineering of bacteria by iron metabolism*
1322 *modulation through MagR expression*. Synth Syst Biotechnol, 2024. **9**(3): p. 522-530.
- 1323 58. Dubiel, S.M., B. Zablotsna-Rypien, and J.B. Mackey, *Magnetic properties of human liver and*
1324 *brain ferritin*. Eur Biophys J, 1999. **28**(3): p. 263-7.
- 1325 59. Guo, R., Zhang, L., Song, D., Yu, B., Song, C., Chen, H., ... & Zhang, X, *Endogenous iron*
1326 *biomineralization in the mouse spleen of metabolic diseases*. Fundamental Research, 2024.
- 1327 60. Feng, C., et al., *Redox imbalance drives magnetic property and function changes in mice*. Redox
1328 Biol, 2025. **81**: p. 103561.

- 1329 61. Peyman, A., *Dielectric properties of tissues; variation with age and their relevance in exposure*
1330 *of children to electromagnetic fields; state of knowledge*. Prog Biophys Mol Biol, 2011. **107**(3):
1331 p. 434-8.
- 1332 62. O'Rourke, A.P., et al., *Dielectric properties of human normal, malignant and cirrhotic liver*
1333 *tissue: in vivo and ex vivo measurements from 0.5 to 20 GHz using a precision open-ended*
1334 *coaxial probe*. Phys Med Biol, 2007. **52**(15): p. 4707-19.
- 1335 63. Lu, Y., et al., *Dielectric properties of human glioma and surrounding tissue*. Int J Hyperthermia,
1336 1992. **8**(6): p. 755-60.
- 1337 64. Huang, S., et al., *Differences in the dielectric properties of various benign and malignant*
1338 *thyroid nodules*. Med Phys, 2021. **48**(2): p. 760-769.
- 1339 65. Barbic, M., *Possible magneto-mechanical and magneto-thermal mechanisms of ion channel*
1340 *activation in magnetogenetics*. Elife, 2019. **8**.
- 1341 66. Bertagna, F., et al., *Effects of electromagnetic fields on neuronal ion channels: a systematic*
1342 *review*. Ann N Y Acad Sci, 2021. **1499**(1): p. 82-103.
- 1343 67. Baureus Koch, C.L., et al., *Interaction between weak low frequency magnetic fields and cell*
1344 *membranes*. Bioelectromagnetics, 2003. **24**(6): p. 395-402.
- 1345 68. Zablotskii, V., T. Polyakova, and A. Dejneka, *Modulation of the Cell Membrane Potential and*
1346 *Intracellular Protein Transport by High Magnetic Fields*. Bioelectromagnetics, 2021. **42**(1): p.
1347 27-36.
- 1348 69. Funk, R.H., T. Monsees, and N. Ozkucur, *Electromagnetic effects - From cell biology to*
1349 *medicine*. Prog Histochem Cytochem, 2009. **43**(4): p. 177-264.
- 1350 70. Huang, W. and D.G. Levitt, *Theoretical calculation of the dielectric constant of a bilayer*
1351 *membrane*. Biophys J, 1977. **17**(2): p. 111-28.
- 1352 71. Bezanilla, F., *Ion channels: from conductance to structure*. Neuron, 2008. **60**(3): p. 456-68.
- 1353 72. Calabro, E., et al., *The inverse relation between mitochondrial transmembrane potential and*
1354 *proteins alpha-helix in neuronal-like cells under static magnetic field and the role of VDAC*.
1355 Electromagn Biol Med, 2020. **39**(2): p. 176-182.
- 1356 73. Uzieliene, I., et al., *The Role of Physical Stimuli on Calcium Channels in Chondrogenic*
1357 *Differentiation of Mesenchymal Stem Cells*. Int J Mol Sci, 2018. **19**(10).
- 1358 74. Jimenez, H., et al., *Tumour-specific amplitude-modulated radiofrequency electromagnetic*
1359 *fields induce differentiation of hepatocellular carcinoma via targeting Ca(v)_{3.2} T-type voltage-*
1360 *gated calcium channels and Ca(2+) influx*. EBioMedicine, 2019. **44**: p. 209-224.
- 1361 75. Gaasch, J.A., et al., *Voltage-gated calcium channels provide an alternate route for iron uptake*
1362 *in neuronal cell cultures*. Neurochem Res, 2007. **32**(10): p. 1686-93.
- 1363 76. Das, S.K. and G.Y. Oudit, *Voltage-gated Ca²⁺ channels as key mediators of iron-transport and*
1364 *iron-overload cardiomyopathy: L-type vs. T-type Ca²⁺ channels*. Eur J Haematol, 2012. **88**(6):
1365 p. 476-7.
- 1366 77. Boag, M.K., et al., *Calcium channels and iron metabolism: A redox catastrophe in Parkinson's*
1367 *disease and an innovative path to novel therapies?* Redox Biol, 2021. **47**: p. 102136.
- 1368 78. Yan, Z., et al., *Magnetic Field Boosts the Transmembrane Transport Efficiency of Magnesium*
1369 *Ions from PLLA Bone Scaffold*. Small, 2023. **19**(40): p. e2301426.

- 1370 79. Ma, S., et al., *A role of PIEZO1 in iron metabolism in mice and humans*. Cell, 2021. **184**(4): p.
1371 969-982 e13.
- 1372 80. Sun, Y., et al., *A static magnetic field enhances the repair of osteoarthritic cartilage by*
1373 *promoting the migration of stem cells and chondrogenesis*. J Orthop Translat, 2023. **39**: p. 43-
1374 54.
- 1375 81. Chu, F., et al., *Transcranial Magneto-Acoustic Stimulation Attenuates Synaptic Plasticity*
1376 *Impairment through the Activation of Piezo1 in Alzheimer's Disease Mouse Model*. Research
1377 (Wash D C), 2023. **6**: p. 0130.
- 1378 82. Lin, Y.C., et al., *Force-induced conformational changes in PIEZO1*. Nature, 2019. **573**(7773):
1379 p. 230-234.
- 1380 83. Lin, L., et al., *Cell Membrane Oscillations under Radiofrequency Electromagnetic Modulation*.
1381 Langmuir, 2023. **39**(9): p. 3320-3331.
- 1382 84. Yang, Z.S., S. Gao, and J.L. Zhang, *Magnetic manipulation of the reactivity of singlet oxygen:*
1383 *from test tubes to living cells*. Natl Sci Rev, 2024. **11**(9): p. nwae069.
- 1384 85. Cecerska-Heryc, E., et al., *The effect of a rotating magnetic field on the antioxidant system in*
1385 *healthy volunteers - preliminary study*. Sci Rep, 2024. **14**(1): p. 8677.
- 1386 86. Mundell, J.W., et al., *Alternating magnetic fields drive stimulation of gene expression via*
1387 *generation of reactive oxygen species*. iScience, 2024. **27**(3): p. 109186.
- 1388 87. Meyer, F., et al., *The effects of radiofrequency electromagnetic field exposure on biomarkers of*
1389 *oxidative stress in vivo and in vitro: A systematic review of experimental studies*. Environ Int,
1390 2024. **194**: p. 108940.
- 1391 88. Hore, P.J. and H. Mouritsen, *The Radical-Pair Mechanism of Magnetoreception*. Annu Rev
1392 Biophys, 2016. **45**: p. 299-344.
- 1393 89. Zadeh-Haghighi, H. and C. Simon, *Magnetic field effects in biology from the perspective of the*
1394 *radical pair mechanism*. J R Soc Interface, 2022. **19**(193): p. 20220325.
- 1395 90. Binhi, V., *Primary physical mechanism of the biological effects of weak magnetic fields*.
1396 Biophysics, 2016. **61**(1): p. 170-176.
- 1397 91. Denton, M.C.J., et al., *Magnetosensitivity of tightly bound radical pairs in cryptochrome is*
1398 *enabled by the quantum Zeno effect*. Nat Commun, 2024. **15**(1): p. 10823.
- 1399 92. Chen, Y., et al., *Oxidative stress induces mitochondrial iron overload and ferroptotic cell death*.
1400 Sci Rep, 2023. **13**(1): p. 15515.
- 1401 93. Zhang, X., et al., *L-selenomethionine inhibits small intestinal ferroptosis caused by ammonia*
1402 *exposure through regulating ROS-mediated iron metabolism*. Ecotoxicol Environ Saf, 2025.
1403 **289**: p. 117477.
- 1404 94. Emerit, J., C. Beaumont, and F. Trivin, *Iron metabolism, free radicals, and oxidative injury*.
1405 Biomed Pharmacother, 2001. **55**(6): p. 333-9.
- 1406 95. Martins, E.A., R.L. Robalinho, and R. Meneghini, *Oxidative stress induces activation of a*
1407 *cytosolic protein responsible for control of iron uptake*. Arch Biochem Biophys, 1995. **316**(1):
1408 p. 128-34.
- 1409 96. Castro, L., et al., *Aconitases: Non-redox Iron-Sulfur Proteins Sensitive to Reactive Species*. Acc
1410 Chem Res, 2019. **52**(9): p. 2609-2619.

- 1411 97. Richardson, D.R. and P. Ponka, *Identification of a mechanism of iron uptake by cells which is*
1412 *stimulated by hydroxyl radicals generated via the iron-catalysed Haber-Weiss reaction.*
1413 *Biochim Biophys Acta*, 1995. **1269**(2): p. 105-14.
- 1414 98. Mladenka, P., et al., *The role of reactive oxygen and nitrogen species in cellular iron*
1415 *metabolism.* *Free Radic Res*, 2006. **40**(3): p. 263-72.
- 1416 99. Aerbajinai, W., et al., *Glia maturation factor-gamma regulates murine macrophage iron*
1417 *metabolism and M2 polarization through mitochondrial ROS.* *Blood Adv*, 2019. **3**(8): p. 1211-
1418 1225.
- 1419 100. Lee, J. and D.H. Hyun, *The Interplay between Intracellular Iron Homeostasis and*
1420 *Neuroinflammation in Neurodegenerative Diseases.* *Antioxidants (Basel)*, 2023. **12**(4).
- 1421 101. Xu, Y., et al., *Ferroptosis and its implications in treating cognitive impairment caused by aging:*
1422 *A study on the mechanism of repetitive transcranial magnetic stimulation.* *Exp Gerontol*, 2024.
1423 **192**: p. 112443.
- 1424 102. Yu, B., et al., *A Static Magnetic Field Improves Iron Metabolism and Prevents High-Fat-*
1425 *Diet/Streptozocin-Induced Diabetes.* *Innovation (Camb)*, 2021. **2**(1): p. 100077.
- 1426 103. Wang, S., et al., *12 T high static magnetic field suppresses osteosarcoma cells proliferation by*
1427 *regulating intracellular ROS and iron status.* *Exp Cell Res*, 2022. **417**(2): p. 113223.
- 1428 104. Zhen, C., et al., *Moderate static magnetic field regulates iron metabolism and salvage bone loss*
1429 *caused by iron accumulation.* *J Orthop Translat*, 2025. **50**: p. 144-157.
- 1430 105. Xue, Y., et al., *Disorder of Iron Metabolism Inhibits the Recovery of Unloading-Induced Bone*
1431 *Loss in Hypomagnetic Field.* *J Bone Miner Res*, 2020. **35**(6): p. 1163-1173.
- 1432 106. Zhang, G., et al., *1-2 T static magnetic field combined with Ferumoxytol prevent unloading-*
1433 *induced bone loss by regulating iron metabolism in osteoclastogenesis.* *J Orthop Translat*, 2023.
1434 **38**: p. 126-140.
- 1435 107. Yu, B., et al., *Effects of gradient high-field static magnetic fields on diabetic mice.* *Zool Res*,
1436 2023. **44**(2): p. 249-258.
- 1437 108. Ren, J., et al., *LF-MF inhibits iron metabolism and suppresses lung cancer through activation*
1438 *of P53-miR-34a-E2F1/E2F3 pathway.* *Sci Rep*, 2017. **7**(1): p. 749.
- 1439 109. Lai, H.C., H.W. Chan, and N.P. Singh, *Effects of radiation from a radiofrequency identification*
1440 *(RFID) microchip on human cancer cells.* *Int J Radiat Biol*, 2016. **92**(3): p. 156-61.
- 1441 110. Weigand, M., Gomez-Pastora, J., Palmer, A., Zborowski, M., Desai, P., & Chalmers, J,
1442 *Continuous-flow magnetic fractionation of red blood cells based on hemoglobin content and*
1443 *oxygen saturation—clinical blood supply implications and sickle cell anemia treatment.*
1444 *Processes*, 2022. **10**(5).
- 1445 111. Zablotskii, V., T. Polyakova, and A. Dejneka, *Exploring Ion Channel Magnetic Pharmacology:*
1446 *Are Magnetic Cues a Viable Alternative to Ion Channel Drugs?* *Bioessays*, 2025. **47**(3): p.
1447 e202400200.
- 1448 112. Patruno, A., et al., *Short ELF-EMF Exposure Targets SIRT1/Nrf2/HO-1 Signaling in THP-1*
1449 *Cells.* *Int J Mol Sci*, 2020. **21**(19).
- 1450 113. Zmyslony, M., et al., *DNA damage in rat lymphocytes treated in vitro with iron cations and*
1451 *exposed to 7 mT magnetic fields (static or 50 Hz).* *Mutat Res*, 2000. **453**(1): p. 89-96.
- 1452 114. Ma, F., et al., *Novel protective effects of pulsed electromagnetic field ischemia/reperfusion*

- 1453 *injury rats*. Biosci Rep, 2016. **36**(6).
- 1454 115. Park, J.E., et al., *Electromagnetic fields induce neural differentiation of human bone marrow*
1455 *derived mesenchymal stem cells via ROS mediated EGFR activation*. Neurochem Int, 2013.
1456 **62**(4): p. 418-24.
- 1457 116. Choi, Y.K., et al., *Stimulation of neural differentiation in human bone marrow mesenchymal*
1458 *stem cells by extremely low-frequency electromagnetic fields incorporated with MNPs*. Appl
1459 Biochem Biotechnol, 2014. **174**(4): p. 1233-1245.
- 1460 117. Vannoni, D., et al., *In vitro exposure of human osteoarthritic chondrocytes to ELF fields and*
1461 *new therapeutic application of musically modulated electromagnetic fields: biological evidence*.
1462 J Biol Regul Homeost Agents, 2012. **26**(1): p. 39-49.
- 1463 118. Hajipour Verdom, B., P. Abdolmaleki, and M. Behmanesh, *The Static Magnetic Field Remotely*
1464 *Boosts the Efficiency of Doxorubicin through Modulating ROS Behaviors*. Sci Rep, 2018. **8**(1):
1465 p. 990.
- 1466 119. Yuan, L.Q., et al., *Induction of apoptosis and ferroptosis by a tumor suppressing magnetic field*
1467 *through ROS-mediated DNA damage*. Aging (Albany NY), 2020. **12**(4): p. 3662-3681.
- 1468 120. Zablotskii, V., T. Polyakova, and A. Dejneka, *Cells in the Non-Uniform Magnetic World: How*
1469 *Cells Respond to High-Gradient Magnetic Fields*. Bioessays, 2018. **40**(8): p. e1800017.
- 1470 121. Goillard, J.M. and E. Marder, *Ion Channel Degeneracy, Variability, and Covariation in*
1471 *Neuron and Circuit Resilience*. Annu Rev Neurosci, 2021. **44**: p. 335-357.
- 1472 122. Trachootham, D., J. Alexandre, and P. Huang, *Targeting cancer cells by ROS-mediated*
1473 *mechanisms: a radical therapeutic approach?* Nat Rev Drug Discov, 2009. **8**(7): p. 579-91.
- 1474 123. Krylov, V.V. and E.A. Osipova, *Molecular Biological Effects of Weak Low-Frequency*
1475 *Magnetic Fields: Frequency-Amplitude Efficiency Windows and Possible Mechanisms*. Int J
1476 Mol Sci, 2023. **24**(13).
- 1477 124. Zhao, Y.Q., et al., *Metabolic iron detection through divalent metal transporter 1 and ferroportin*
1478 *mediated cocktail fluorogenic probes*. Chem Commun (Camb), 2021. **57**(64): p. 7902-7905.
- 1479 125. Jareonsettasin, P., et al., *Multiple Time Courses of Vestibular Set-Point Adaptation Revealed by*
1480 *Sustained Magnetic Field Stimulation of the Labyrinth*. Curr Biol, 2016. **26**(10): p. 1359-66.
- 1481 126. Zastko, L., et al., *Intermittent ELF-MF Induce an Amplitude-Window Effect on Umbilical Cord*
1482 *Blood Lymphocytes*. Int J Mol Sci, 2022. **23**(22).
- 1483 127. Lai, H. and B.B. Levitt, *Cellular and molecular effects of non-ionizing electromagnetic fields*.
1484 Rev Environ Health, 2024. **39**(3): p. 519-529.
- 1485 128. Elferchichi, M., H. Abdelmelek, and M. Sakly, *Effects of sub-acute exposure to static magnetic*
1486 *field on iron status and hematopoiesis in rats*. Turk J Haematol, 2007. **24**(2): p. 54-68.
- 1487 129. Akdag, M.Z., et al., *Effect of ELF magnetic fields on lipid peroxidation, sperm count, p53, and*
1488 *trace elements*. Med Sci Monit, 2006. **12**(11): p. BR366-71.
- 1489 130. Devevey, L., et al., *Can 50 Hz magnetic fields alter iron metabolism and induce anaemia?* Int
1490 J Radiat Biol, 2000. **76**(12): p. 1669-76.
- 1491 131. Dong, D., et al., *16 T high static magnetic field inhibits receptor activator of nuclear factor*
1492 *kappa-Beta ligand-induced osteoclast differentiation by regulating iron metabolism in*
1493 *Raw264.7 cells*. J Tissue Eng Regen Med, 2019. **13**(12): p. 2181-2190.

- 1494 132. Jajte, J., et al., *Effect of 7 mT static magnetic field and iron ions on rat lymphocytes: apoptosis,*
1495 *necrosis and free radical processes.* Bioelectrochemistry, 2002. **57**(2): p. 107-111.
- 1496 133. Fang, X., et al., *The molecular and metabolic landscape of iron and ferroptosis in*
1497 *cardiovascular disease.* Nat Rev Cardiol, 2023. **20**(1): p. 7-23.
- 1498 134. Wang, S., et al., *Moderate static magnetic field promotes fracture healing and regulates iron*
1499 *metabolism in mice.* Biomed Eng Online, 2023. **22**(1): p. 107.
- 1500 135. Aldinucci, C., et al., *Effects of 50 Hz electromagnetic fields on rat cortical synaptosomes.*
1501 *Toxicol Ind Health*, 2009. **25**(4-5): p. 249-52.
- 1502 136. Lee, H.N., et al., *Ferritin is associated with neural differentiation of bone marrow-derived*
1503 *mesenchymal stem cells under extremely low-frequency electromagnetic field.* Cell Mol Biol
1504 (Noisy-le-grand), 2015. **61**(7): p. 55-9.
- 1505 137. Consales, C., et al., *50-Hz magnetic field impairs the expression of iron-related genes in the in*
1506 *vitro SOD1(G93A) model of amyotrophic lateral sclerosis.* Int J Radiat Biol, 2019. **95**(3): p.
1507 368-377.
- 1508 138. Song, C., et al., *Magnetic Fields Affect Alcoholic Liver Disease by Liver Cell Oxidative Stress*
1509 *and Proliferation Regulation.* Research (Wash D C), 2023. **6**: p. 0097.
- 1510 139. Wang, Y., et al., *A Paramagnetic Metal-Organic Framework Enhances Mild Magnetic*
1511 *Hyperthermia Therapy by Downregulating Heat Shock Proteins and Promoting Ferroptosis via*
1512 *Aggravation of Two-Way Regulated Redox Dyshomeostasis.* Adv Sci (Weinh), 2024. **11**(11): p.
1513 e2306178.
- 1514 140. Lv, Z., et al., *Bifunctional TRPV1 Targeted Magnetothermal Switch to Attenuate Osteoarthritis*
1515 *Progression.* Research (Wash D C), 2024. **7**: p. 0316.
- 1516 141. Li, R., et al., *Enhancing the effects of transcranial magnetic stimulation with intravenously*
1517 *injected magnetic nanoparticles.* Biomater Sci, 2019. **7**(6): p. 2297-2307.
- 1518 142. Marycz, K., et al., *Iron oxides nanoparticles (IOs) exposed to magnetic field promote expression*
1519 *of osteogenic markers in osteoblasts through integrin alpha-3 (INTa-3) activation, inhibits*
1520 *osteoclasts activity and exerts anti-inflammatory action.* J Nanobiotechnology, 2020. **18**(1): p.
1521 33.
- 1522 143. Chen, M., et al., *Homogenous multifunctional microspheres induce ferroptosis to promote the*
1523 *anti-hepatocarcinoma effect of chemoembolization.* J Nanobiotechnology, 2022. **20**(1): p. 179.
- 1524 144. Bayanzay, K. and L. Alzoebie, *Reducing the iron burden and improving survival in transfusion-*
1525 *dependent thalassemia patients: current perspectives.* J Blood Med, 2016. **7**: p. 159-69.
- 1526 145. Miryam, E., et al., *Effects of acute exposure to static magnetic field on ionic composition of rat*
1527 *spinal cord.* Gen Physiol Biophys, 2010. **29**(3): p. 288-94.
- 1528 146. Aida, L., et al., *Effects of static magnetic field exposure on plasma element levels in rat.* Biol
1529 *Trace Elem Res*, 2014. **160**(1): p. 67-72.
- 1530 147. Elferchichi, M., et al., *Effects of exposure to static magnetic field on motor skills and iron levels*
1531 *in plasma and brain of rats.* Brain Inj, 2011. **25**(9): p. 901-8.
- 1532 148. Elferchichi, M., et al., *Subacute static magnetic field exposure in rat induces a pseudoanemia*
1533 *status with increase in MCT4 and Glut4 proteins in glycolytic muscle.* Environ Sci Pollut Res
1534 *Int*, 2016. **23**(2): p. 1265-73.
- 1535 149. Hachulla, E., et al., *Pseudo-iron deficiency in a French population living near high-voltage*

- 1536 *transmission lines: a dilemma for clinicians*. Eur J Intern Med, 2000. **11**(6): p. 351-2.
- 1537 150. Cetkin, M., et al., *Evaluation of the mobile phone electromagnetic radiation on serum iron*
1538 *parameters in rats*. Afr Health Sci, 2017. **17**(1): p. 186-190.
- 1539 151. Oscar, K.J. and T.D. Hawkins, *Microwave alteration of the blood-brain barrier system of rats*.
1540 Brain Res, 1977. **126**(2): p. 281-93.
- 1541 152. Nittby, H., et al., *Radiofrequency and extremely low-frequency electromagnetic field effects on*
1542 *the blood-brain barrier*. Electromagn Biol Med, 2008. **27**(2): p. 103-26.
- 1543 153. Lai, H. and N.P. Singh, *Magnetic-field-induced DNA strand breaks in brain cells of the rat*.
1544 Environ Health Perspect, 2004. **112**(6): p. 687-94.
- 1545 154. Elferchichi, M., et al., *Effects of combined ferrous sulfate administration and exposure to static*
1546 *magnetic field on brain oxidative stress and emotional behavior*. Arch Ital Biol, 2015. **153**(1):
1547 p. 37-45.
- 1548 155. Maaroufi, K., et al., *Effects of combined ferrous sulphate administration and exposure to static*
1549 *magnetic field on spatial learning and motor abilities in rats*. Brain Inj, 2013. **27**(4): p. 492-9.
- 1550 156. Aldinucci, C., et al., *Synaptosome behaviour is unaffected by weak pulsed electromagnetic*
1551 *fields*. Bioelectromagnetics, 2007. **28**(6): p. 477-83.
- 1552 157. Maaroufi, K., et al., *Spatial learning, monoamines and oxidative stress in rats exposed to 900*
1553 *MHz electromagnetic field in combination with iron overload*. Behav Brain Res, 2014. **258**: p.
1554 80-9.
- 1555 158. Tian, H., et al., *System-level biological effects of extremely low-frequency electromagnetic fields:*
1556 *an in vivo experimental review*. Front Neurosci, 2023. **17**: p. 1247021.
- 1557 159. Cordelli, E., et al., *Effects of radiofrequency electromagnetic field (RF-EMF) exposure on male*
1558 *fertility: A systematic review of experimental studies on non-human mammals and human sperm*
1559 *in vitro*. Environ Int, 2024. **185**: p. 108509.
- 1560 160. Zhang, Y.Y., et al., *Tumor iron homeostasis and immune regulation*. Trends Pharmacol Sci,
1561 2024. **45**(2): p. 145-156.
- 1562 161. Tsao, C.W., et al., *Effects of Iron Supplementation on Testicular Function and Spermatogenesis*
1563 *of Iron-Deficient Rats*. Nutrients, 2022. **14**(10).
- 1564 162. Rastegar Panah, M., et al., *Biomarkers of Iron Are Associated with Anterior-Pituitary-Produced*
1565 *Reproductive Hormones in Men with Infertility*. Nutrients, 2024. **16**(2).
- 1566 163. Ni, S., et al., *Iron Metabolism and Immune Regulation*. Front Immunol, 2022. **13**: p. 816282.
- 1567 164. Touitou, Y., et al., *Long-term (up to 20 years) effects of 50-Hz magnetic field exposure on*
1568 *immune system and hematological parameters in healthy men*. Clinical biochemistry, 2013.
1569 **46**(1-2): p. 59-63.
- 1570 165. Gobba, F., et al., *Extremely low frequency-magnetic fields (ELF-EMF) occupational exposure*
1571 *and natural killer activity in peripheral blood lymphocytes*. Science of the total environment,
1572 2009. **407**(3): p. 1218-1223.
- 1573 166. Han, Y., et al., *Rotating magnetic field mitigates ankylosing spondylitis targeting osteocytes*
1574 *and chondrocytes via ameliorating immune dysfunctions*. Cells, 2023. **12**(7): p. 972.
- 1575 167. Yao, C., L. Zhao, and R. Peng, *The biological effects of electromagnetic exposure on immune*
1576 *cells and potential mechanisms*. Electromagn Biol Med, 2022. **41**(1): p. 108-117.

- 1577 168. Zhou, Y., et al., *Iron overloaded polarizes macrophage to proinflammation phenotype through*
1578 *ROS/acetyl-p53 pathway*. *Cancer Med*, 2018. **7**(8): p. 4012-4022.
- 1579 169. Wosik, J., et al., *Macrophage phenotype bioengineered by magnetic, genetic, or pharmacologic*
1580 *interference*. *Immunol Res*, 2019. **67**(1): p. 1-11.
- 1581 170. Gobba, F., et al., *Natural killer cell activity decreases in workers occupationally exposed to*
1582 *extremely low frequency magnetic fields exceeding 1 μ T*. *International Journal of*
1583 *Immunopathology and Pharmacology*, 2009. **22**(4): p. 1059-1066.
- 1584 171. House, R.V. and D.L. McCormick, *Modulation of natural killer cell function after exposure to*
1585 *60 Hz magnetic fields: confirmation of the effect in mature B6C3F1 mice*. *Radiation Research*,
1586 2000. **153**(5): p. 722-724.
- 1587 172. Lin, S.-L., et al., *Enhancement of natural killer cell cytotoxicity by using static magnetic field*
1588 *to increase their viability*. *Electromagnetic Biology and Medicine*, 2019. **38**(2): p. 131-142.
- 1589 173. Kuźmicka, W., et al., *Iron excess affects release of neutrophil extracellular traps and reactive*
1590 *oxygen species but does not influence other functions of neutrophils*. *Immunology and Cell*
1591 *Biology*, 2022. **100**(2): p. 87-100.
- 1592 174. Hua, Y., et al., *Iron overload may promote alteration of NK cells and hematopoietic*
1593 *stem/progenitor cells by JNK and P38 pathway in myelodysplastic syndromes*. *International*
1594 *Journal of Hematology*, 2017. **106**: p. 248-257.
- 1595 175. Chi, H., M. Pepper, and P.G. Thomas, *Principles and therapeutic applications of adaptive*
1596 *immunity*. *Cell*, 2024. **187**(9): p. 2052-2078.
- 1597 176. Zmyslony, M., et al., *Acute exposure to 930 MHz CW electromagnetic radiation in vitro affects*
1598 *reactive oxygen species level in rat lymphocytes treated by iron ions*. *Bioelectromagnetics*, 2004.
1599 **25**(5): p. 324-8.
- 1600 177. Zmyslony, M., et al., *The effect of weak 50 Hz magnetic fields on the number of free oxygen*
1601 *radicals in rat lymphocytes in vitro*. *Bioelectromagnetics*, 2004. **25**(8): p. 607-12.
- 1602 178. Carter, T.J., et al., *Potential of magnetic hyperthermia to stimulate localized immune activation*.
1603 *Small*, 2021. **17**(14): p. 2005241.
- 1604 179. Xi, X., et al., *The association between iron metabolism with the change of blood pressure and*
1605 *risk of hypertension: A large cross-sectional study*. *J Trace Elem Med Biol*, 2023. **79**: p. 127193.
- 1606 180. Signorelli, S.S., et al., *Oxidative Status, Iron Plasma Levels in Venous Thrombosis Patients*.
1607 *Antioxidants (Basel)*, 2024. **13**(6).
- 1608 181. Dos Santos, L., et al., *Iron overload, oxidative stress and vascular dysfunction: Evidences from*
1609 *clinical studies and animal models*. *Biochim Biophys Acta Gen Subj*, 2022. **1866**(9): p. 130172.
- 1610 182. Okano, H. and C. Ohkubo, *Effects of neck exposure to 5.5 mT static magnetic field on*
1611 *pharmacologically modulated blood pressure in conscious rabbits*. *Bioelectromagnetics*, 2005.
1612 **26**(6): p. 469-80.
- 1613 183. Stewart, G.M., et al., *Impact of pulsed electromagnetic field therapy on vascular function and*
1614 *blood pressure in hypertensive individuals*. *J Clin Hypertens (Greenwich)*, 2020. **22**(6): p. 1083-
1615 1089.
- 1616 184. Li, Q., et al., *Moderate Intensity Static Magnetic Fields Prevent Thrombus Formation in Rats*
1617 *and Mice*. *Bioelectromagnetics*, 2020. **41**(1): p. 52-62.
- 1618 185. Libby, P., *The changing landscape of atherosclerosis*. *Nature*, 2021. **592**(7855): p. 524-533.

- 1619 186. Wunderer, F., et al., *The role of hepcidin and iron homeostasis in atherosclerosis*. Pharmacol
1620 Res, 2020. **153**: p. 104664.
- 1621 187. Xu, S., *Iron and Atherosclerosis: The Link Revisited*. Trends Mol Med, 2019. **25**(8): p. 659-
1622 661.
- 1623 188. Javadzadegan, A., A. Moshfegh, and M. Behnia, *Effect of magnetic field on haemodynamic
1624 perturbations in atherosclerotic coronary arteries*. J Med Eng Technol, 2018. **42**(2): p. 148-
1625 156.
- 1626 189. Abdi, S., et al., *Evaluation of the effects of weak and moderate static magnetic fields on the
1627 characteristics of human low density lipoprotein in vitro*. Bioelectromagnetics, 2013. **34**(5): p.
1628 397-404.
- 1629 190. Gorobets, O., et al., *Modulation of calcium signaling and metabolic pathways in endothelial
1630 cells with magnetic fields*. Nanoscale Adv, 2024. **6**(4): p. 1163-1182.
- 1631 191. Li, Y., et al., *Low strength static magnetic field inhibits the proliferation, migration, and
1632 adhesion of human vascular smooth muscle cells in a restenosis model through mediating
1633 integrins beta1-FAK, Ca²⁺ signaling pathway*. Ann Biomed Eng, 2012. **40**(12): p. 2611-8.
- 1634 192. Ma, T., et al., *Electromagnetic fields regulate calcium-mediated cell fate of stem cells:
1635 osteogenesis, chondrogenesis and apoptosis*. Stem Cell Res Ther, 2023. **14**(1): p. 133.
- 1636 193. Zhang, M., et al., *Ischemia-reperfusion injury: molecular mechanisms and therapeutic targets*.
1637 Signal Transduct Target Ther, 2024. **9**(1): p. 12.
- 1638 194. Ma, S., et al., *Protective effects of low-frequency magnetic fields on cardiomyocytes from
1639 ischemia reperfusion injury via ROS and NO/ONOO*. Oxid Med Cell Longev, 2013. **2013**: p.
1640 529173.
- 1641 195. Andrade, C., *Antidepressant Prescription in Pregnancy: The Importance of Prenatal Maternal
1642 Anemia as a Potential Confound in Studies on Neurodevelopmental and Other Outcomes*. J Clin
1643 Psychiatry, 2020. **81**(2).
- 1644 196. Long, H., et al., *Iron homeostasis imbalance and ferroptosis in brain diseases*. MedComm
1645 (2020), 2023. **4**(4): p. e298.
- 1646 197. Wu, Q., et al., *Brain Iron Homeostasis and Mental Disorders*. Antioxidants (Basel), 2023.
1647 **12**(11).
- 1648 198. Feng, Z., et al., *Iron overload in the motor cortex induces neuronal ferroptosis following spinal
1649 cord injury*. Redox Biol, 2021. **43**: p. 101984.
- 1650 199. Wincek, A., et al., *The Long-Term Effect of Treatment Using the Transcranial Magnetic
1651 Stimulation rTMS in Patients after Incomplete Cervical or Thoracic Spinal Cord Injury*. J Clin
1652 Med, 2021. **10**(13).
- 1653 200. Dey, S., et al., *Extremely low frequency magnetic field protects injured spinal cord from the
1654 microglia- and iron-induced tissue damage*. Electromagn Biol Med, 2017. **36**(4): p. 330-340.
- 1655 201. Liao, L.L., et al., *Treatment of spinal cord injury with mesenchymal stem cells*. Cell Biosci,
1656 2020. **10**: p. 112.
- 1657 202. Skalnikova, H., et al., *A proteomic approach to studying the differentiation of neural stem cells*.
1658 Proteomics, 2007. **7**(11): p. 1825-38.
- 1659 203. Jeong, W.Y., et al., *Extremely low-frequency electromagnetic field promotes astrocytic
1660 differentiation of human bone marrow mesenchymal stem cells by modulating SIRT1 expression*.

- 1661 Biosci Biotechnol Biochem, 2017. **81**(7): p. 1356-1362.
- 1662 204. Kim, H.J., et al., *Extremely low-frequency electromagnetic fields induce neural differentiation*
1663 *in bone marrow derived mesenchymal stem cells*. Exp Biol Med (Maywood), 2013. **238**(8): p.
1664 923-31.
- 1665 205. Carmona, U., et al., *Ferritin light-chain subunits: key elements for the electron transfer across*
1666 *the protein cage*. Chem Commun (Camb), 2014. **50**(97): p. 15358-61.
- 1667 206. Pal, A., et al., *Iron oxide nanoparticles and magnetic field exposure promote functional*
1668 *recovery by attenuating free radical-induced damage in rats with spinal cord transection*. Int J
1669 Nanomedicine, 2013. **8**: p. 2259-72.
- 1670 207. Katsnelson, A., B. De Strooper, and H.Y. Zoghbi, *Neurodegeneration: From cellular concepts*
1671 *to clinical applications*. Sci Transl Med, 2016. **8**(364): p. 364ps18.
- 1672 208. Chen, L., et al., *Homeostasis and metabolism of iron and other metal ions in neurodegenerative*
1673 *diseases*. Signal Transduct Target Ther, 2025. **10**(1): p. 31.
- 1674 209. Wang, Z.L., et al., *Ferroptosis in Parkinson's disease: glia-neuron crosstalk*. Trends Mol Med,
1675 2022. **28**(4): p. 258-269.
- 1676 210. Bao, W.D., et al., *Loss of ferroportin induces memory impairment by promoting ferroptosis in*
1677 *Alzheimer's disease*. Cell Death Differ, 2021. **28**(5): p. 1548-1562.
- 1678 211. Hautot, D., et al., *Preliminary evaluation of nanoscale biogenic magnetite in Alzheimer's*
1679 *disease brain tissue*. Proc Biol Sci, 2003. **270 Suppl 1**(Suppl 1): p. S62-4.
- 1680 212. Soares, P., et al., *Drug discovery and amyotrophic lateral sclerosis: Emerging challenges and*
1681 *therapeutic opportunities*. Ageing Res Rev, 2023. **83**: p. 101790.
- 1682 213. Johnson, E.B., et al., *Altered iron and myelin in premanifest Huntington's Disease more than*
1683 *20 years before clinical onset: Evidence from the cross-sectional HD Young Adult Study*.
1684 EBioMedicine, 2021. **65**: p. 103266.
- 1685 214. Lee, S. and G.G. Kovacs, *The Irony of Iron: The Element with Diverse Influence on*
1686 *Neurodegenerative Diseases*. Int J Mol Sci, 2024. **25**(8).
- 1687 215. Crapper McLachlan, D.R., et al., *Intramuscular desferrioxamine in patients with Alzheimer's*
1688 *disease*. Lancet, 1991. **337**(8753): p. 1304-8.
- 1689 216. Devos, D., et al., *Trial of Deferiprone in Parkinson's Disease*. N Engl J Med, 2022. **387**(22): p.
1690 2045-2055.
- 1691 217. Mitsui, T., et al., *Efficacy of Repetitive Trans-spinal Magnetic Stimulation for Patients with*
1692 *Parkinson's Disease: a Randomised Controlled Trial*. Neurotherapeutics, 2022. **19**(4): p. 1273-
1693 1282.
- 1694 218. Bagattini, C., et al., *Enhancing cognitive training effects in Alzheimer's disease: rTMS as an*
1695 *add-on treatment*. Brain Stimul, 2020. **13**(6): p. 1655-1664.
- 1696 219. Musaro, A., et al., *Neuromuscular magnetic stimulation counteracts muscle decline in ALS*
1697 *patients: results of a randomized, double-blind, controlled study*. Sci Rep, 2019. **9**(1): p. 2837.
- 1698 220. Wang, Z., et al., *Moderate strength (0.23-0.28 T) static magnetic fields (SMF) modulate*
1699 *signaling and differentiation in human embryonic cells*. BMC Genomics, 2009. **10**: p. 356.
- 1700 221. Wang, Z., et al., *Static magnetic field exposure reproduces cellular effects of the Parkinson's*
1701 *disease drug candidate ZM241385*. PLoS One, 2010. **5**(11): p. e13883.

- 1702 222. Peggion, C., et al., *SOD1 in ALS: Taking Stock in Pathogenic Mechanisms and the Role of Glial*
1703 *and Muscle Cells*. Antioxidants (Basel), 2022. **11**(4).
- 1704 223. Tasset, I., et al., *Extremely low-frequency electromagnetic fields activate the antioxidant*
1705 *pathway Nrf2 in a Huntington's disease-like rat model*. Brain Stimul, 2013. **6**(1): p. 84-6.
- 1706 224. Weiler, M., et al., *Transcriptional changes in the rat brain induced by repetitive transcranial*
1707 *magnetic stimulation*. Front Hum Neurosci, 2023. **17**: p. 1215291.
- 1708 225. Lu, Y., et al., *Regulation and Role of Neuron-Derived Hemoglobin in the Mouse Hippocampus*.
1709 Int J Mol Sci, 2022. **23**(10).
- 1710 226. Zheng, R., et al., *Physiological and Pathological Functions of Neuronal Hemoglobin: A Key*
1711 *Underappreciated Protein in Parkinson's Disease*. Int J Mol Sci, 2022. **23**(16).
- 1712 227. Perez, F.P., et al., *Multidimensional insights into the repeated electromagnetic field stimulation*
1713 *and biosystems interaction in aging and age-related diseases*. J Biomed Sci, 2022. **29**(1): p. 39.
- 1714 228. Sun, S., et al., *Brain Disease-Modifying Effects of Radiofrequency as a Non-Contact Neuronal*
1715 *Stimulation Technology*. Int J Mol Sci, 2025. **26**(5).
- 1716 229. Afshari, M., et al., *Reversing valproic acid-induced autism-like behaviors through a*
1717 *combination of low-frequency repeated transcranial magnetic stimulation and*
1718 *superparamagnetic iron oxide nanoparticles*. Sci Rep, 2024. **14**(1): p. 8082.
- 1719 230. Bassett, C.A., R.J. Pawluk, and A.A. Pilla, *Augmentation of bone repair by inductively coupled*
1720 *electromagnetic fields*. Science, 1974. **184**(4136): p. 575-7.
- 1721 231. Zhang, H., et al., *The influence of iron on bone metabolism disorders*. Osteoporos Int, 2024.
1722 **35**(2): p. 243-253.
- 1723 232. Sun, K., et al., *Iron homeostasis in arthropathies: From pathogenesis to therapeutic potential*.
1724 Ageing Res Rev, 2021. **72**: p. 101481.
- 1725 233. Ru, Q., et al., *Fighting age-related orthopedic diseases: focusing on ferroptosis*. Bone Res, 2023.
1726 **11**(1): p. 12.
- 1727 234. Yang, J., et al., *Iron Deficiency and Iron Deficiency Anemia: Potential Risk Factors in Bone*
1728 *Loss*. Int J Mol Sci, 2023. **24**(8).
- 1729 235. Luo, C., et al., *Canonical Wnt signaling works downstream of iron overload to prevent*
1730 *ferroptosis from damaging osteoblast differentiation*. Free Radic Biol Med, 2022. **188**: p. 337-
1731 350.
- 1732 236. Wang, X., et al., *Iron-induced oxidative stress stimulates osteoclast differentiation via NF-*
1733 *kappaB signaling pathway in mouse model*. Metabolism, 2018. **83**: p. 167-176.
- 1734 237. Schaefer, B., H. Zoller, and M. Wolf, *Risk Factors for and Effects of Persistent and Severe*
1735 *Hypophosphatemia Following Ferric Carboxymaltose*. J Clin Endocrinol Metab, 2022. **107**(4):
1736 p. 1009-1019.
- 1737 238. Sarrai, M., et al., *Bone mass density in adults with sickle cell disease*. Br J Haematol, 2007.
1738 **136**(4): p. 666-72.
- 1739 239. Bordbar, M.R., et al., *Evaluation of bone mineral density in children with sickle-cell anemia*
1740 *and its associated factors in the south of Iran: a case-control study*. Arch Osteoporos, 2017.
1741 **12**(1): p. 70.
- 1742 240. Eskiocak, O., M.O. Yilmaz, and G. Ilhan, *Metabolic bone diseases in sickle cell anemia patients*

- 1743 *and evaluation of associated factors*. Am J Med Sci, 2022. **363**(6): p. 490-494.
- 1744 241. Kim, B.J., et al., *Iron overload accelerates bone loss in healthy postmenopausal women and*
1745 *middle-aged men: a 3-year retrospective longitudinal study*. J Bone Miner Res, 2012. **27**(11):
1746 p. 2279-90.
- 1747 242. Kim, B.J., et al., *The association between higher serum ferritin level and lower bone mineral*
1748 *density is prominent in women ≥ 45 years of age (KNHANES 2008-2010)*. Osteoporos Int,
1749 2013. **24**(10): p. 2627-37.
- 1750 243. Zhu, F., et al., *Electric/Magnetic Intervention for Bone Regeneration: A Systematic Review and*
1751 *Network Meta-Analysis*. Tissue Eng Part B Rev, 2023. **29**(3): p. 217-231.
- 1752 244. Yang, J., et al., *Static magnetic field of 0.2-0.4 T promotes the recovery of hindlimb unloading-*
1753 *induced bone loss in mice*. Int J Radiat Biol, 2021. **97**(5): p. 746-754.
- 1754 245. Wang, J., et al., *A 0.2 T-0.4 T Static Magnetic Field Improves the Bone Quality of Mice*
1755 *Subjected to Hindlimb Unloading and Reloading Through the Dual Regulation of BMSCs via*
1756 *Iron Metabolism*. Int J Mol Sci, 2024. **25**(23).
- 1757 246. Yang, J., et al., *Regulation of Osteoblast Differentiation and Iron Content in MC3T3-E1 Cells*
1758 *by Static Magnetic Field with Different Intensities*. Biol Trace Elem Res, 2018. **184**(1): p. 214-
1759 225.
- 1760 247. Yang, J., et al., *Effect of High Static Magnetic Fields on Biological Activities and Iron*
1761 *Metabolism in MLO-Y4 Osteocyte-like Cells*. Cells, 2021. **10**(12).
- 1762 248. Lv, H., et al., *A static magnetic field improves bone quality and balances the function of bone*
1763 *cells with regulation on iron metabolism and redox status in type 1 diabetes*. FASEB J, 2023.
1764 **37**(7): p. e22985.
- 1765 249. Aghajanian, P. and S. Mohan, *The art of building bone: emerging role of chondrocyte-to-*
1766 *osteoblast transdifferentiation in endochondral ossification*. Bone Res, 2018. **6**: p. 19.
- 1767 250. Wang, Q., et al., *Osteogenic differentiation of amniotic epithelial cells: synergism of pulsed*
1768 *electromagnetic field and biochemical stimuli*. BMC Musculoskelet Disord, 2014. **15**: p. 271.
- 1769 251. Yang, J., Q. Tang, and Y. Zeng, *Melatonin: Potential avenue for treating iron overload*
1770 *disorders*. Ageing Res Rev, 2022. **81**: p. 101717.
- 1771 252. Huang, J., et al., *Combined Effects of Low-Frequency Pulsed Electromagnetic Field and*
1772 *Melatonin on Ovariectomy-Induced Bone Loss in Mice*. Bioelectromagnetics, 2021. **42**(8): p.
1773 616-628.
- 1774 253. Yang, J., et al., *Iron overload involved in the enhancement of unloading-induced bone loss by*
1775 *hypomagnetic field*. Bone, 2018. **114**: p. 235-245.
- 1776 254. Jia, B., et al., *A hypomagnetic field aggravates bone loss induced by hindlimb unloading in rat*
1777 *femurs*. PLoS One, 2014. **9**(8): p. e105604.
- 1778 255. Zhang, J., C. Ding, and P. Shang, *Alterations of mineral elements in osteoblast during*
1779 *differentiation under hypo, moderate and high static magnetic fields*. Biol Trace Elem Res, 2014.
1780 **162**(1-3): p. 153-7.
- 1781 256. Hooiveld, M.J., et al., *Immature articular cartilage is more susceptible to blood-induced*
1782 *damage than mature articular cartilage: an in vivo animal study*. Arthritis Rheum, 2003. **48**(2):
1783 p. 396-403.
- 1784 257. van Vulpen, L.F., et al., *The detrimental effects of iron on the joint: a comparison between*

- 1785 *haemochromatosis and haemophilia*. J Clin Pathol, 2015. **68**(8): p. 592-600.
- 1786 258. Wang, W., et al., *Iron overload promotes intervertebral disc degeneration via inducing*
1787 *oxidative stress and ferroptosis in endplate chondrocytes*. Free Radic Biol Med, 2022. **190**: p.
1788 234-246.
- 1789 259. Yao, X., et al., *Chondrocyte ferroptosis contribute to the progression of osteoarthritis*. J Orthop
1790 Translat, 2021. **27**: p. 33-43.
- 1791 260. Guo, Z., et al., *Deferoxamine Alleviates Osteoarthritis by Inhibiting Chondrocyte Ferroptosis*
1792 *and Activating the Nrf2 Pathway*. Front Pharmacol, 2022. **13**: p. 791376.
- 1793 261. Radakovich, L.B., et al., *Systemic iron reduction via an iron deficient diet decreases the severity*
1794 *of knee cartilage lesions in the Dunkin-Hartley guinea pig model of osteoarthritis*. Osteoarthritis
1795 Cartilage, 2022. **30**(11): p. 1482-1494.
- 1796 262. Tanski, W., et al., *Iron metabolism in patients with rheumatoid arthritis*. Eur Rev Med
1797 Pharmacol Sci, 2021. **25**(12): p. 4325-4335.
- 1798 263. Zhang, C., et al., *Iron deficiency accelerates intervertebral disc degeneration through affecting*
1799 *the stability of DNA polymerase epsilon complex*. Am J Transl Res, 2018. **10**(11): p. 3430-3442.
- 1800 264. Miller, S.L., et al., *Pulsed electromagnetic field (PEMF) treatment reduces expression of genes*
1801 *associated with disc degeneration in human intervertebral disc cells*. Spine J, 2016. **16**(6): p.
1802 770-6.
- 1803 265. Wang, T., et al., *Effects of electromagnetic fields on osteoarthritis*. Biomed Pharmacother, 2019.
1804 **118**: p. 109282.
- 1805 266. Ross, C.L., D.C. Ang, and G. Almeida-Porada, *Targeting Mesenchymal Stromal Cells/Pericytes*
1806 *(MSCs) With Pulsed Electromagnetic Field (PEMF) Has the Potential to Treat Rheumatoid*
1807 *Arthritis*. Front Immunol, 2019. **10**: p. 266.
- 1808 267. Bi, D., et al., *Effects of rotating and stationary magnetic fields on serum iron in rheumatoid*
1809 *arthritis rat*. Progress in Modern Biomedicine, 2008. **8**(12): p. 3.
- 1810 268. Jin, E.J., et al., *Ferroptosis and iron metabolism in diabetes: Pathogenesis, associated*
1811 *complications, and therapeutic implications*. Front Endocrinol (Lausanne), 2024. **15**: p.
1812 1447148.
- 1813 269. Harrison, A.V., F.R. Lorenzo, and D.A. McClain, *Iron and the Pathophysiology of Diabetes*.
1814 Annu Rev Physiol, 2023. **85**: p. 339-362.
- 1815 270. Liu, P., et al., *Ferroptosis: Mechanisms and role in diabetes mellitus and its complications*.
1816 Ageing Res Rev, 2024. **94**: p. 102201.
- 1817 271. Tassone, E.E., J.C. Page, and M.J. Slepian, *Assessing the Effects of Pulsed Electromagnetic*
1818 *Therapy on Painful Diabetic Distal Symmetric Peripheral Neuropathy: A Double-Blind*
1819 *Randomized Controlled Trial*. J Diabetes Sci Technol, 2025. **19**(2): p. 361-369.
- 1820 272. Carter, C.S., et al., *Exposure to Static Magnetic and Electric Fields Treats Type 2 Diabetes*.
1821 Cell Metab, 2022. **34**(11): p. 1893.
- 1822 273. Djordjevich, D.M., et al., *Hematological parameters' changes in mice subchronically exposed*
1823 *to static magnetic fields of different orientations*. Ecotoxicol Environ Saf, 2012. **81**: p. 98-105.
- 1824 274. Volani, C., et al., *Dietary iron loading negatively affects liver mitochondrial function*.
1825 Metallomics, 2017. **9**(11): p. 1634-1644.

- 1826 275. Suzuki, Y., et al., *Up-regulation of transferrin receptor expression in hepatocytes by habitual*
1827 *alcohol drinking is implicated in hepatic iron overload in alcoholic liver disease.* Alcohol Clin
1828 Exp Res, 2002. **26**(8 Suppl): p. 26S-31S.
- 1829 276. Bridle, K., et al., *Hepcidin is down-regulated in alcoholic liver injury: implications for the*
1830 *pathogenesis of alcoholic liver disease.* Alcohol Clin Exp Res, 2006. **30**(1): p. 106-12.
- 1831 277. Suzuki, M., et al., *Induction of transferrin receptor by ethanol in rat primary hepatocyte culture.*
1832 Alcohol Clin Exp Res, 2004. **28**(8 Suppl Proceedings): p. 98S-105S.
- 1833 278. Li, L.X., et al., *Iron overload in alcoholic liver disease: underlying mechanisms, detrimental*
1834 *effects, and potential therapeutic targets.* Cell Mol Life Sci, 2022. **79**(4): p. 201.
- 1835 279. Wang, X., et al., *Effects of 1.5-9.4 T High Static Magnetic Fields on Alcoholic Liver Disease in*
1836 *Mice.* J Magn Reson Imaging, 2024.
- 1837 280. Lv, H., et al., *Exposure to a static magnetic field attenuates hepatic damage and function*
1838 *abnormality in obese and diabetic mice.* Biochim Biophys Acta Mol Basis Dis, 2023. **1869**(6):
1839 p. 166719.
- 1840 281. Rupp, T., J. Montet, and J.W. Frazer, *A comparison of thermal and radio-frequency exposure*
1841 *effects on trace metal content of blood plasma and liver cell fractions of rodents.* Ann N Y Acad
1842 Sci, 1975. **247**: p. 282-91.
- 1843 282. Maffei, M.E., *Magnetic Fields and Cancer: Epidemiology, Cellular Biology, and Theranostics.*
1844 Int J Mol Sci, 2022. **23**(3).
- 1845 283. Jimenez, H., et al., *Use of non-ionizing electromagnetic fields for the treatment of cancer.* Front
1846 Biosci (Landmark Ed), 2018. **23**(2): p. 284-297.
- 1847 284. Zhu, M., et al., *The efficacy and safety of low-frequency rotating static magnetic field therapy*
1848 *combined with chemotherapy on advanced lung cancer patients: a randomized, double-blinded,*
1849 *controlled clinical trial.* Int J Radiat Biol, 2020. **96**(7): p. 943-950.
- 1850 285. Salnikow, K., *Role of iron in cancer.* Semin Cancer Biol, 2021. **76**: p. 189-194.
- 1851 286. Torti, S.V. and F.M. Torti, *Iron: The cancer connection.* Mol Aspects Med, 2020. **75**: p. 100860.
- 1852 287. Adachi, M., et al., *Transferrin receptor 1 overexpression is associated with tumour de-*
1853 *differentiation and acts as a potential prognostic indicator of hepatocellular carcinoma.*
1854 Histopathology, 2019. **75**(1): p. 63-73.
- 1855 288. Chen, F., et al., *Integrated analysis identifies TfR1 as a prognostic biomarker which correlates*
1856 *with immune infiltration in breast cancer.* Aging (Albany NY), 2021. **13**(17): p. 21671-21699.
- 1857 289. Shesh, B.P. and J.R. Connor, *A novel view of ferritin in cancer.* Biochim Biophys Acta Rev
1858 Cancer, 2023. **1878**(4): p. 188917.
- 1859 290. Brookes, M.J., et al., *Modulation of iron transport proteins in human colorectal carcinogenesis.*
1860 Gut, 2006. **55**(10): p. 1449-60.
- 1861 291. Pinnix, Z.K., et al., *Ferroportin and iron regulation in breast cancer progression and prognosis.*
1862 Sci Transl Med, 2010. **2**(43): p. 43ra56.
- 1863 292. Jiang, X.P., R.L. Elliott, and J.F. Head, *Manipulation of iron transporter genes results in the*
1864 *suppression of human and mouse mammary adenocarcinomas.* Anticancer Res, 2010. **30**(3): p.
1865 759-65.
- 1866 293. Liu, B., et al., *Downregulation of FPN1 acts as a prognostic biomarker associated with immune*

- 1867 *infiltration in lung cancer*. Aging (Albany NY), 2021. **13**(6): p. 8737-8761.
- 1868 294. Xue, D., et al., *Decreased expression of ferroportin in prostate cancer*. Oncol Lett, 2015. **10**(2):
1869 p. 913-916.
- 1870 295. Capareli, F., et al., *Low-energy amplitude-modulated electromagnetic field exposure: Feasibility study in patients with hepatocellular carcinoma*. Cancer Med, 2023. **12**(11): p.
1871 12402-12412.
- 1872
- 1873 296. Mai, Y., et al., *The strategies to cure cancer patients by eradicating cancer stem-like cells*. Mol
1874 Cancer, 2023. **22**(1): p. 171.
- 1875 297. Wang, W., et al., *Therapy-resistant nature of cancer stem cells in view of iron metabolism*.
1876 Inflamm Regen, 2022. **42**(1): p. 34.
- 1877 298. Su, Y., et al., *Ferroptosis, a novel pharmacological mechanism of anti-cancer drugs*. Cancer
1878 Lett, 2020. **483**: p. 127-136.
- 1879 299. Miyazawa, M., A.R. Bogdan, and Y. Tsuji, *Perturbation of Iron Metabolism by Cisplatin through Inhibition of Iron Regulatory Protein 2*. Cell Chem Biol, 2019. **26**(1): p. 85-97 e4.
1880
- 1881 300. Tofani, S., et al., *Static and ELF magnetic fields enhance the in vivo anti-tumor efficacy of cisplatin against lewis lung carcinoma, but not of cyclophosphamide against B16 melanotic melanoma*. Pharmacol Res, 2003. **48**(1): p. 83-90.
1882 1883
- 1884 301. Chen, W.F., et al., *Static magnetic fields enhanced the potency of cisplatin on k562 cells*. Cancer
1885 Biother Radiopharm, 2010. **25**(4): p. 401-8.
- 1886 302. Kamalipooya, S., et al., *Simultaneous application of cisplatin and static magnetic field enhances oxidative stress in HeLa cell line*. In Vitro Cell Dev Biol Anim, 2017. **53**(9): p. 783-790.
1887
- 1888 303. Yuan, L.Q., et al., *The antitumor effect of static and extremely low frequency magnetic fields against nephroblastoma and neuroblastoma*. Bioelectromagnetics, 2018. **39**(5): p. 375-385.
1889
- 1890 304. Zafari, J., et al., *Static magnetic field reduces cisplatin resistance via increasing apoptosis pathways and genotoxicity in cancer cell lines*. Sci Rep, 2024. **14**(1): p. 5792.
1891
- 1892 305. Zhang, C., et al., *Synthesis of Iron Nanometallic Glasses and Their Application in Cancer Therapy by a Localized Fenton Reaction*. Angew Chem Int Ed Engl, 2016. **55**(6): p. 2101-6.
1893
- 1894 306. Lamkowsky, M.C., et al., *Magnetic field-induced acceleration of the accumulation of magnetic iron oxide nanoparticles by cultured brain astrocytes*. J Biomed Mater Res A, 2012. **100**(2): p. 323-34.
1895 1896
- 1897 307. Min, K.A., et al., *Pulsed magnetic field improves the transport of iron oxide nanoparticles through cell barriers*. ACS Nano, 2013. **7**(3): p. 2161-71.
1898
- 1899 308. Pan, J., et al., *Mild Magnetic Hyperthermia-Activated Innate Immunity for Liver Cancer Therapy*. J Am Chem Soc, 2021. **143**(21): p. 8116-8128.
1900
- 1901 309. Sadhukha, T., et al., *Effective elimination of cancer stem cells by magnetic hyperthermia*. Mol Pharm, 2013. **10**(4): p. 1432-41.
1902
- 1903 310. Kang, N., et al., *Stimuli-responsive ferroptosis for cancer therapy*. Chem Soc Rev, 2023. **52**(12):
1904 p. 3955-3972.
- 1905 311. Li, Z., et al., *The Therapeutic Effects of MUC1-C shRNA@Fe(3)O(4) Magnetic Nanoparticles in Alternating Magnetic Fields on Triple-Negative Breast Cancer*. Int J Nanomedicine, 2023. **18**: p. 5651-5670.
1906 1907

- 1908 312. Jiang, B., et al., *Standardized assays for determining the catalytic activity and kinetics of*
1909 *peroxidase-like nanozymes*. Nat Protoc, 2018. **13**(7): p. 1506-1520.
- 1910 313. Zhang, Y., et al., *The applications of nanozymes in cancer therapy: based on regulating*
1911 *pyroptosis, ferroptosis and autophagy of tumor cells*. Nanoscale, 2023. **15**(29): p. 12137-12156.
- 1912 314. Yuan, Y., et al., *MOFs-Based Magnetic Nanozyme to Boost Cascade ROS Accumulation for*
1913 *Augmented Tumor Ferroptosis*. Adv Healthc Mater, 2024: p. e2304591.
- 1914 315. Orel, V., et al., *Magnetic properties and antitumor effect of nanocomplexes of iron oxide and*
1915 *doxorubicin*. Nanomedicine, 2015. **11**(1): p. 47-55.
- 1916 316. Falone, S., et al., *Power frequency magnetic field promotes a more malignant phenotype in*
1917 *neuroblastoma cells via redox-related mechanisms*. Sci Rep, 2017. **7**(1): p. 11470.
- 1918
- 1919
- 1920
- 1921
- 1922
- 1923

Figures and Tables





Figure 1. The characteristics and classification of electromagnetic fields (EMFs). According to whether the magnetic field intensity varies with time, EMFs can be divided into static magnetic field (SMF) and times-varying magnetic field. SMFs can be further categorized by increasing magnetic field intensity into hypomagnetic fields (HyMFs, <5 μ T), weak static magnetic fields (WSMFs, 5 μ T to 1 mT), moderate static magnetic fields (MSMFs, 1 mT to 1 T), and high static magnetic fields (HiSMFs, >1 T). HyMFs include natural environments, such as the lunar surface, as well as artificial environments, which can be generated using devices like Helmholtz coils. The geomagnetic field (20–70 μ T) is the most commonly encountered WSMF for living organisms. MSMFs are typically produced by permanent magnets, while HiSMFs are primarily generated by superconducting devices such as MRI systems. Time-varying magnetic fields are further subdivided by increasing frequency into extremely low-frequency electromagnetic fields (ELF-EMFs, 0–100 kHz) and radiofrequency electromagnetic fields (RF-EMFs, 100 kHz–300 GHz), among others. ELF-EMFs in daily life commonly originate from power transmission lines and electrical appliances. In the biomedical field, devices like transcranial magnetic stimulation (TMS) systems and rotating magnetic field (RMF) generators also produce ELF-EMFs. RF-EMFs from mobile communication systems are the most common form of RF-EMF exposure in daily life. Additionally, RF-EMFs are widely used in the medical field, such as in diathermy devices for therapeutic applications.



1950

1951 **Figure 2.** Systemic and cellular iron metabolism. **(a)**, The duodenal enterocytes absorb
 1952 approximately 1-2mg of dietary iron daily to compensate for nonspecific iron losses. Plasma
 1953 iron is bound to transferrin, the majority of which is utilized for hemoglobin synthesis in
 1954 erythroid cells in the bone marrow, while a smaller portion is stored or used by other cells in
 1955 various tissues. Macrophages can phagocytose damaged or senescent red blood cells, releasing
 1956 the iron from hemoglobin back into the plasma, which accounts for more than 90% of the
 1957 plasma iron pool. The unused iron is reversibly stored in liver and spleen. Hepcidin, the core
 1958 regulator of systemic iron metabolism, is primarily produced in hepatocytes and can inactivate
 1959 ferroportin (FPN) in target cells, thereby inhibiting iron efflux to the bloodstream. **(b)**,
 1960 Transferrin-bound iron is taken up through transferrin receptor (TfR), then the iron is reduced
 1961 from Fe^{3+} to Fe^{2+} by six-transmembrane epithelial antigen of prostate3 (STEAP3) in
 1962 vesicles and enters the cytoplasm via divalent metal transporter 1 (DMT1). Cells can also take
 1963 up the non-transferrin-bound iron (NTBI) directly through ion channels like DMT1, Zinc
 1964 transporters Zrt- and Irt-like protein 8 (ZIP8) and ZIP14. Moreover, heme and ferritin can be
 1965 transported directly into the cell by specific molecules, including CD91, HRG1, FLVCR2,
 1966 and Scara5. Fe^{2+} in the labile iron pool (LIP) can be stored in ferritin and can also be
 1967 utilized in various biochemical processes. Iron in ferritin can be released back into the LIP
 1968 through Nuclear receptor coactivator 4 (NCOA4) mediated ferritinophagy. Most active
 1969 iron enters the mitochondria via mitoferrins (MFRNs) for the synthesis of Fe-S clusters and
 1970 heme. FPN exports excess Fe^{2+} from cells, where it is oxidized to Fe^{3+} by ceruloplasmin (Cp)
 1971 and subsequently binds to transferrin. Additionally, NCOA4 can mediate the export of ferritin,
 1972 while FLVCR1 is believed to mediate the extracellular export of heme. Hepcidin-FPN axis,
 1973 iron-regulatory protein (IRP)-iron-responsive element (IRE) network, and nuclear factor
 1974 erythroid 2-related factor 2 (NRF2) pathway are critically involved in the regulation of
 1975 systemic and cellular iron metabolism.




Figure 3. The potential biophysical mechanisms and characteristics of electromagnetic fields (EMFs) in regulating iron metabolism. (a) EMF exposure involves various parameters, including field intensity, gradient, frequency, and exposure duration. (b-d) Potential biophysical mechanisms of EMF regulation of iron metabolism. (b) The direct effects of EMFs on iron-containing tissue and proteins. Iron content influences the electromagnetic properties of tissue and cells, including magnetic permeability, electrical conductivity, and dielectric constants, thereby affecting their response to EMFs; EMFs alter the movement of iron-containing proteins and molecules, such as hemoglobin and ferritin, thus impacting iron metabolism; Furthermore, EMFs modulate the dynamic characteristics of iron-containing proteins/molecules, thereby regulating iron metabolism, such as regulating the release and storage of iron in ferritin. (c) EMFs regulate iron metabolism by influencing transmembrane transport of iron through the modulation of cell membranes and ion channels. EMFs could regulate voltage-gated ion channels (VGCs) mediated iron uptake by adjusting membrane potential, and mechanosensitive ion channels (piezo1, etc) mediated iron uptake by inducing membrane deformation. (d) Due to the close interplay between reactive oxygen species (ROS) and iron metabolism, EMFs can regulate iron metabolism by altering intracellular ROS levels through mechanisms such as affecting the spin state of radical pairs. (e) The regulation of iron metabolism by EMFs exhibits distinct characteristics, including parameter specificity, window effects, and tissue- and cell- specificity.




Figure 4. Electromagnetic fields influence various physiological processes and the progression of diseases by regulating iron metabolism.

2004

2005 Table 1 The effects of EMFs on iron metabolism in nervous system

EMF type	Parameters	Objects	Exposure time	Iron metabolism change	Outcome	Reference
SMF	MSMF	128 mT	Rats	1 h/day, for 5 days	Brain content/iron unchanged	Synergistically exacerbated anxiety levels in rats when combined with FeSO ₄ , but no synergistic effects on spatial learning abilities [147, 154, 155]
	MSMF	0.23 T–0.28 T	PC12	1 h	Iron uptake/decreased	Counteracted several PD-relevant endpoints exacerbated by A(2A)R agonist CGS21680 [221]
Time-varying magnetic fields	ELF-EMF	25 Hz rTMS	Mice	14 days and 28 days	FTH1, NRF2 / increased TfR1 and hippocampal iron content/decreased	Enhanced cognitive function and augments cerebral activity [101]
	ELF-EMF	17.96 μ T, 50 Hz	Rats	2 h/day for 8 weeks	Iron content in injury area/increased	Promoted vascular regeneration, reduce lesion volume and inflammation following spinal cord injury [200]
	ELF-EMF	60 Hz, 10 μ T	Rats	24 h		Increased the DNA damage in brain, which inhibited by [153]

					iron chelator deferiprone	
ELF- EMF	50Hz , 17.96μT	Rats	2 h/day for 5 weeks		Synergistical ly promoted the repair of spinal cord injury with nanoparticles	[206]
ELF- EMF	60 Hz, 0.7 T	Rats	4 h/day for 8 days	NRF2 increased	/	[223]
RF- EMF	900 MHz , 100 mW	Rats	1 h/day for 21 days		No synergistic effect between 900MHz EMF and FeSO4 on spatial learning	[157]
RF- EMF	1788 MHz	Rabbits	150 min	iron deposition in cerebellum/ increased		[31]
ELF- EMF	60 Hz, 30 μT	Nonlactating pregnant Holstein cows	2.05 h/day, 30 days	Iron in blood plasma/unchang ed Iron in cerebrospinal fluid/decreased		[21]
ELF- EMF	60 Hz, 30 μT	Nonlactating nonpregnant ovariectomize d heifers	2.05 h/day, 30 days	Iron in blood plasma/unchang ed Iron in cerebrospinal fluid/ unchanged		[21]
ELF- EMF	50 Hz, 1 mT	hBMSCs	6 days		Synergistic Promoted neural Differentiatio n with Fe3O4 nanoparticles	[116]

ELF-EMF	50 mT	Hz, 1	hBMSCs	12 days	FTH1 and FTL / increased	Promoted the neural differentiation	[136, 204]
ELF-EMF	50 mT	Hz, 1	SOD1 ^{G93A} mutant SH-SY5Y cells	24- 72 h	TFR1, IRP1, and MFRN1 / decreased		[137]
ELF-EMF	50 mT	Hz, 2	Synaptosomes	2 h	Iron release/unchanged	Physiological behavior of cortical synaptosomes was unaffected	[135, 156]

2006

2007

2008

2009 **Table 2** The effects of EMFs on iron metabolism in orthopedic diseases

EMF type	Parameters	Objects	Exposure time	Iron metabolism change	Outcome	Reference
				Liver, spleen, bone marrow, diaphysis, and serum iron content/increased		
	HyMF 300 nT	Mice	28 days	Serum ferritin content/increased Hepcidin in liver/increased FPN in liver/decreased TfR1, FTH1, and FPN in tibia/decreased	Aggravated HLU induced bone loss ; Inhibited the recovery of HLU induced bone loss	[105, 253]
SMF	HyMF 300 nT	Rats	28 days	Serum iron content/increased	Aggravated HLU induced bone loss	[254]
				Serum hepcidin/increased		
	MSMF 0.05 T~0.5 T	Mice	14 days , 28 days	Serum ferritin/decreased iron content in callus/decreased	Promoted fracture healing	[134]
	MSMF 0.4T-0.7 T	Type diabetic mice	1 4 h/day for 6 weeks	Tibial iron content/increased TfR1, FTH1, and FPN in tibia/increased	Inhibited diabetes induced boss	[248]

HiSM F	1 T-2 T	Mice	1 h/day, 28 days	Serum iron/decreased Iron in femur/decreased	Inhibited hindlimb unloading induced bone loss and bone resorption	[106]
HyMF	500 nT	MC3T3-E1	48 hours	Iron content, TfR1 /increased FTH1, FTL, and FPN/ unchanged	Increased ALP and COL-1 expression; Decreased DMP1 expression	[246]
HyMF	500 nT	MC3T3-E1	10 days	iron content/increase d	Inhibited osteogenic differentiation	[255]
MSM F	0.2 T	MC3T3-E1	48 hours	Iron content, TfR1, and FTL /unchanged FTH1, FPN/increased	Decreased ALP and DMP1 expression	[246]
HiSM F	16 T	MC3T3-E1	48 hours	Iron content, TfR1/decreased FPN/increased FTH1 and FTL/ unchanged	Increased ALP, OCN, COL-1, DMP1, and OPN expression	[246]
HiSM F	16 T	MLO-Y4	48 hours	Iron content, DMT1/ increased FPN/decreased FTH1/unchange d	Increased CX43 expression; Deceased sost expression and secretion	[247]
HiSM F	1 T-2 T	RAW264.7	1 h/day for 28 days	TfR1 and FPN/unchanged FTH1/decreased iron uptake of IONPs/decrease	Inhibited osteoclastogene sis	[106]

d

	HiSMF	16 T	RAW264.7	48 hours	Iron content, TfR1, and decreased FPN/increased	DMT1, FTH1/ Inhibited osteoclast differentiation	[131]
	RMF	6.72 Hz and 8.97 Hz, 0.4 T,	Rats	2 h/time, twice a day for 30 days	Serum content transferrin/ increased	iron and Alleviated induced swelling	RA joint [267]
Time-varying magnetic fields	ELF-MF	50Hz, mT	1	Amniotic epithelial cells	30 min/time, twice a day for 21 days	NRF2/increased	Promoted osteogenic differentiation [250]
	RF-MF	1MHz	Mouse primary chondrocytes		FTH1 /increased NCOA4/decreased	Inhibited tert-butyl hydroperoxide-induced ferroptosis	[140]

2010

2011

2012

2013 **Table 3** The effects of EMFs on cancer iron metabolism


EMF type	Parameters	Objects	Exposure time	Iron metabolism change	Outcome	Reference
SMF	MSMF	10 mT	MCF-7	24 h, 48 h	Iron content/decreased	Inhibited proliferation [118]
					LIP / increased	
	MSMF	0.2-0.4 T	K7M2 stem cells, MG63 stem cells	7 days	FTH1/decreased NCOA4/increased	Improved self-renewal ability [55]
	HiSMF	12 T	MNNG/HOS, U-2 OS, and MG63	48 h	Iron content, LIP/increased FTH1, DMT1/increased TfR1, FPN/unchanged	Inhibited proliferation [103]
Time-varying magnetic fields	ELF-EMF	7.5 Hz, 0.4 T	LLC	2h/day, 3 days	TfR1, FTH1/decreased	Inhibited proliferation [108]
	ELF-EMF	7.5 Hz, 0.4 T	Lewis lung cancer murine model	2h/day, 35 days	TfR1, FTH1/decreased	Inhibited lung cancer growth [108]
	ELF-EMF	50 Hz, 1 mT	SH-SY5Y		NRF2/increased	Increased resistance to doxorubicin and H ₂ O ₂ [316]
	ELF-EMF	50 Hz, 5.1 mT	G401, A549 cells	2 h/day, 3 days		Inhibited proliferation, which could be attenuated by ferrostatin-1 [119]

RF-EMF	134 KHz	Molt-4, BT474, and HepG2	1 h	Inhibited proliferation, which could be attenuated by deferoxamine [109]
	3 kW, 60 min	HCC-70	FTH1, NRF2/decreased	Enhanced the inhibitory ability of Fe3O4 NPs on cell viability and cell migration. [311]

2014

2015

2016



2017

2018 Electromagnetic fields (EMFs) can influence the progression of various diseases by
 2019 regulating iron metabolism.

2020 The regulation of iron metabolism by EMFs is highly parameter-specific and varies
 2021 across different tissues and cells.

2022 The unique electromagnetic properties of iron-containing molecules/proteins and iron-
 2023 enriched tissues play a role in the regulation of iron metabolism by EMFs.

2024 EMFs can modulate iron metabolism through their effects on membrane structure and
 2025 ion channels.

2026 EMFs can modulate iron metabolism by regulating the generation and activity of
 2027 reactive oxygen species (ROS).

2028




2029

2030 **Shenghang Wang** is a postdoctoral fellow at the People's Hospital of Longhua. He
2031 received his Ph.D. from Northwestern Polytechnical University. His research focuses
2032 primarily on the biosafety of electromagnetic fields, their effects on iron metabolism,
2033 and the mechanisms by which electromagnetic fields regulate the progression of
2034 orthopedic diseases.



2035

2036 **Jiancheng Yang**, Ph.D., is an associate researcher at Honghui Hospital, Xi'an Jiaotong
2037 University. He graduated from Northwestern Polytechnical University and his main
2038 research focuses on bone metabolism and iron metabolism under special physical
2039 environments such as magnetic fields and weightlessness. He has published more than
2040 20 SCI papers as the first author or corresponding author, and has led one National
2041 Natural Science Foundation of China, two provincial projects, and two municipal
2042 projects.



2043

2044 **Chenxiao Zhen** is a postdoctoral fellow at the People's Hospital of Longhua. She
2045 received her Ph.D from Northwestern Polytechnical University. She is mainly engaged
2046 in magnetic biology research. Her research focuses on the biological effects of high

2047 magnetic field, moderate magnetic field and hypomagnetic field environment on the
2048 skeletal system. At present, as the first author, she has published three research articles
2049 and two review articles in internationally recognized peer-reviewed journals.



2050

2051 **Huiru Wang** is currently studying for a master's degree at Northwestern Polytechnical
2052 University. Her main research area is the relationship between the thermal and non-
2053 thermal effects of electromagnetic fields with varying parameters and their biosafety,
2054 as well as their applications in the treatment of orthopedic diseases.



2055

2056 **Peng Shang** is a professor and doctoral supervisor at the Research & Development
2057 Institute of Northwestern Polytechnical University in Shenzhen. His primary fields of
2058 research are the biomedical foundations of the skeletal system under conditions of
2059 weightlessness, radiation, and electromagnetic fields in space, as well as teaching,
2060 research, and the application of bioelectromagnetic technology in the field of bone
2061 health. He looks forward to developing new electromagnetic field devices for the
2062 treatment of orthopedic diseases.

2063

2064 **Compliance with Ethics Requirements**

2065 This article does not contain any studies with human or animal subjects.

2066 **Declaration of competing interest**

2067 No potential conflict of interest was reported by the authors.

2068

Journal Pre-proofs